Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-02-10T14:53:48.112Z Has data issue: false hasContentIssue false

Drugs as instruments: A new framework for non-addictive psychoactive drug use

Published online by Cambridge University Press:  10 November 2011

Christian P. Müller
Affiliation:
Section of Addiction Medicine, Department of Psychiatry and Psychotherapy, University of Erlangen–Nuremberg, 91054 Erlangen, Germany. christian.mueller@uk-erlangen.dehttp://www.psychiatrie.uk-erlangen.de/wir_ueber_uns/mitarbeiter/e3000/index_ger.html MRC SGDP-Center, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom. Gunter.Schumann@kcl.ac.ukhttp://www.iop.kcl.ac.uk/staff/profile/default.aspx?go=10977
Gunter Schumann
Affiliation:
Section of Addiction Medicine, Department of Psychiatry and Psychotherapy, University of Erlangen–Nuremberg, 91054 Erlangen, Germany. christian.mueller@uk-erlangen.dehttp://www.psychiatrie.uk-erlangen.de/wir_ueber_uns/mitarbeiter/e3000/index_ger.html
Rights & Permissions [Opens in a new window]

Abstract

Most people who are regular consumers of psychoactive drugs are not drug addicts, nor will they ever become addicts. In neurobiological theories, non-addictive drug consumption is acknowledged only as a “necessary” prerequisite for addiction, but not as a stable and widespread behavior in its own right. This target article proposes a new neurobiological framework theory for non-addictive psychoactive drug consumption, introducing the concept of “drug instrumentalization.” Psychoactive drugs are consumed for their effects on mental states. Humans are able to learn that mental states can be changed on purpose by drugs, in order to facilitate other, non-drug-related behaviors. We discuss specific “instrumentalization goals” and outline neurobiological mechanisms of how major classes of psychoactive drugs change mental states and serve non-drug-related behaviors. We argue that drug instrumentalization behavior may provide a functional adaptation to modern environments based on a historical selection for learning mechanisms that allow the dynamic modification of consummatory behavior. It is assumed that in order to effectively instrumentalize psychoactive drugs, the establishment of and retrieval from a drug memory is required. Here, we propose a new classification of different drug memory subtypes and discuss how they interact during drug instrumentalization learning and retrieval. Understanding the everyday utility and the learning mechanisms of non-addictive psychotropic drug use may help to prevent abuse and the transition to drug addiction in the future.

Type
Target Article
Copyright
Copyright © Cambridge University Press 2011

1. Introduction

1.1. Non-addictive drug use

The use of drugs is a widespread phenomenon in many societies of the world, even though there are cultural differences influencing the kinds of drugs used and the ways in which drugs are taken (Heath Reference Heath2000; Kuntsche et al. Reference Kuntsche, Knibbe, Gmel and Engels2006). The U.S. National Survey on Drug Use and Health (NSDUH 2007) revealed that approximately 19.9 million Americans (8% of the population) aged 12 or older consumed at least one illicit drug such as marijuana/hashish, cocaine, heroin, hallucinogens, solvents, or prescription-type psychotherapeutics. More than 50% of Americans aged 12 or older reported they were current drinkers of alcohol, and more than 28.6% of Americans aged 12 or older used tobacco products. European surveys revealed that in the general population of the 15-to-64-year-olds, about 324 million people (84%) drank alcohol daily. A recent survey (EMCDDA 2009) estimating illicit drug use by response to a question about “last month's use” determined current cannabis users at 12.5 million people (3.7%) and cocaine users at 2.0 million people (0.5%).

It has been established beyond any doubt that drug addiction is a major psychiatric disorder that causes harm to the individual, to the social environment, and to society (American Psychiatric Association 1994). Much research is devoted to understanding and curing drug addiction. Epidemiological data show, however, that the majority of people who consume psychoactive drugs with an addiction potential are not addicts and will never become addicted (Glynn et al. Reference Glynn, LoCastro, Hermos and Bosse1983; O'Malley & Johnston Reference O'Malley and Johnston2002; Zinberg & Jacobson Reference Zinberg and Jacobson1976; Zinberg et al. Reference Zinberg, Harding, Stelmack and Marblestone1978). Of those people who are classified as current alcohol drinkers in the United States, 14.9% are diagnosed as addicts based on the SAMHSA (2005) report. Among the 20.4 million current users (use in the previous month) of illicit drugs in the United States – which include marijuana, cocaine, heroin, hallucinogens, solvents, and prescription-type drugs – 34.3% have been estimated to be addicts (SAMHSA 2005). European Union estimates are similar. In the European Union, about 7.1% of the daily drinkers of alcohol are alcohol dependent (Anderson & Baumberg Reference Anderson and Baumberg2006), whereas about 32% of the current cannabis consumers show a problematic consumption (EMCDDA 2009). In a U.S. National Comorbidity Survey, the cumulative risk until the age of 54 to fulfill criteria for dependence to marijuana is 10%; for cocaine, up to 21% (until age 40); and for alcohol, about 20% (Chen & Anthony Reference Chen and Anthony2004; Wagner & Anthony Reference Wagner and Anthony2002). From surveys of this kind, it is clear that the majority of psychoactive drug users are not and will never be drug addicts (Heyman Reference Heyman1996). Although drug addiction is an undeniable, major burden to society, to a considerable degree, use of psychoactive drugs is unrelated to addiction.

1.2. Psychoactive drug use

In this article, we regard a drug (a single chemical compound with unique structure) as psychoactive when it (a) interacts with the function of the central nervous system (CNS) and (b) changes subjective experience, behavior, or both. Whereas considerable research effort has been made to understand drug addiction and how it develops (Hill & Newlin Reference Hill and Newlin2002; West Reference West2006), an adaptive role or beneficial effect for psychoactive drugs is often categorically denied (e.g., Sullivan et al. Reference Sullivan, Hagen and Hammerstein2008). Without an account of non-addictive drug use, conceptualizing the transition between non-addictive to addicted drug use is difficult. In this article, we suggest that people use psychoactive drugs not because their reward systems have been “hijacked,” but to advance specific behaviors relevant for their own “fitness.”

2. Widening the explanatory scope for drug use

The consumption of psychoactive drugs is usually considered a maladaptation, particularly in people with genetic or environmental risks that make them prone to addiction (e.g., Campbell et al. Reference Campbell, Szumlinski and Kippin2009; Schumann Reference Schumann2007; Schumann et al. Reference Schumann, Rujescu, Kissling, Soyka, Dahmen, Preuss, Wieman, Depner, Wellek, Lascorz, Bondy, Giegling, Anghelescu, Cowen, Poustka, Spanagel, Mann, Henn and Szegedi2003; Reference Schumann, Johann, Frank, Preuss, Dahmen, Laucht, Rietschel, Rujescu, Lourdusamy, Clarke, Krause, Dyer, Depner, Wellek, Treutlein, Szegedi, Giegling, Cichon, Blomeyer, Heinz, Heath, Lathrop, Wodarz, Soyka, Spanagel and Mann2008). Many drugs that humans consume are plant toxins, such as nicotine, cocaine, or cannabis, which serve as plant defenses and prevent plant consumption. The widely accepted evolutionary adaptation of these toxins for plants is to deter herbivores (e.g., Nathanson et al. Reference Nathanson, Hunnicutt, Kantham and Scavone1993). Why certain plants develop substances that reinforce plant consumption and why any organism should have a mechanism that reinforces the toxin consumption are therefore a puzzle. This apparent evolutionary contradiction has been termed the “paradox of drug reward” (Hagen et al. Reference Hagen, Sullivan, Schmidt, Morris, Kempter and Hammerstein2009; Sullivan & Hagen Reference Sullivan and Hagen2002; Sullivan et al. Reference Sullivan, Hagen and Hammerstein2008).

Dosage is one aspect of the resolution of this paradox. Drugs like cocaine induce euphoria only at low to medium doses. At higher doses, cocaine induces highly aversive paranoia and behavioral stereotypes (Gawin Reference Gawin1991; Gawin & Kleber Reference Gawin and Kleber1986; Kramer et al. Reference Kramer, Fischman and Littlefield1967). Drugs with a low euphoria component, such as nicotine or caffeine, are voluntarily consumed, usually at low, non-toxic doses (Cauli & Morelli Reference Cauli and Morelli2005). It is important to realize that the doses in which humans and animals voluntarily consume psychoactive drugs are usually below the acute toxic range (Gable Reference Gable2004; Hagen et al. Reference Hagen, Sullivan, Schmidt, Morris, Kempter and Hammerstein2009). As such, the general “paradox of drug reward” may be resolved at the dose-response level: In a low- to medium-dose range, the drug effect is not toxic in the sense of being an immediate threat to life. In the range of medium to low doses, therefore, a role for drugs in functional adaptation can reasonably be considered (Chisholm Reference Chisholm1999).

A number of alternative views seek to explain the development and persistence of psychoactive drug consumption. The behavior may, hence, be based on (1) a fitness-irrelevant hijacking of generic motivational systems, (2) a fitness-irrelevant but subjectively perceived improvement in a variety of fitness-relevant motivational states specific to important goals, or (3) an actual improvement in success in these same motivational states.

  1. 1. Nesse and Berridge (Reference Nesse and Berridge1997) have argued that those psychoactive drugs that induce positive emotions might provide at the same time a false fitness benefit signal, which in turn “hijacks” incentive salience mechanisms, such as “wanting” and “liking” in the brain. For positive as well as negative emotions, a clear fitness benefit can be identified, in that these emotions can be conceptualized as “specialized states shaped to cope with situations that involve the opportunities or gains and a great number of different kinds of situations that involve threats or losses” (Nesse & Berridge Reference Nesse and Berridge1997). This evolutionary approach expanded the reinforcement-centered explanations for drug taking by an emotional perspective in that drugs are consumed to change emotions in a broad sense, not just for relatively narrow euphoria/hedonia. Although this can be done safely in some circumstances, it might leave the organism with less fitness when the natural function of emotion is constantly circumvented or “hijacked” (Nesse & Berridge Reference Nesse and Berridge1997; Panksepp et al. Reference Panksepp, Knutson and Burgdorf2002).

  2. 2. Newlin (Reference Newlin2002) suggested that drugs are taken to “inflate” the “self-perceived survival ability and reproduction fitness” (SPFit). SPFit is a concept for the mammalian motivation to enhance and protect survival and reproductive fitness, much related to the feelings of personal power and sexual attractiveness. Indeed, it could be shown that common drugs like alcohol, if taken in moderate amounts, increase the subjective perception of power in humans (Wilsnack Reference Wilsnack1974). Although it was argued that drugs enhance this subjective feeling, Newlin (Reference Newlin2002) denies a potential evolutionary benefit.

  3. 3. Some authors have at least raised the possibility of actual short- (Lende & Smith Reference Lende and Smith2002) and long-term beneficial effects of drug use (Hagen et al. Reference Hagen, Sullivan, Schmidt, Morris, Kempter and Hammerstein2009). Viewing drug use as an evolutionary adaptation, Lende and Smith (Reference Lende and Smith2002) argued that the adaptive function of drug use is to provide an individual with a predictable short-term pleasure in an unsafe environment, where the pursuit of natural reinforcers can only be poorly established. Drug addiction is then seen as a maladaptation based on a missing built-in regulatory function in the salience signaling mesolimbic dopamine (DA) system (Lende & Smith Reference Lende and Smith2002). Lende and colleagues (2007) analyzed the behavioral function of methamphetamine in a population of heavy users in Atlanta, Georgia (United States). They interviewed users for their perceived functions of use and identified three main categories: (1) enhanced function, (2) increased productivity, and (3) functioning normally. This study revealed an important detail: methamphetamine users did not perceive their drug use to impair their daily functioning, but rather to enhance it (Lende et al. Reference Lende, Leonard, Sterk and Elifson2007).

Several authors have acknowledged the subjectively perceived psychological benefits of drug consumption (Baum-Baicker Reference Baum-Baicker1985; Chick Reference Chick1999; Peele & Brodsky Reference Peele and Brodsky2000). These subjectively reported and objectively measured benefits are related to a moderate and non-compulsive– that is, non-addictive – consumption of alcohol and comprise fields such as subjective health, mood enhancement, stress reduction, sociability, mental health, long-term cognitive functioning, and work performance (Chick Reference Chick1999; Molnar et al. Reference Molnar, Busseri, Perrier and Sadava2009; Peele & Brodsky Reference Peele and Brodsky2000). In addition, there is evidence for beneficial effects of methamphetamine use on everyday function (Lende Reference Lende, Wenda Trevathan, Smith and McKenna2007; Lende et al. Reference Lende, Leonard, Sterk and Elifson2007).

Overall, several researchers have recognized subjectively reported beneficial effects of certain consumption patterns and have reviewed in much detail the evidence for it. However, a systematic analysis of drug taking as either a functional adaptation or, alternatively, as a beneficial effect of current adaptations is still in its infancy. As such, a general principle for non-addictive psychoactive drug consumption has yet to emerge. The presented functional analysis of non-addictive psychoactive drug consumption suggests that psychoactive drug use does indeed result in an improvement of fitness-relevant behavior. It also suggests that humans are able to subjectively perceive or cognitively reflect – or both – not only the improved outcome of behavior, but also the rather systematic use of the behavior “psychoactive drug consumption.”

3. Why do human beings consume psychoactive drugs? A drug instrumentalization framework

We propose that the large majority of non-addicted humans who consume psychoactive drugs as a normal part of their lives, take drugs because the drugs' effects are useful for their personal goals. Psychoactive drugs can be instrumentalized. We refer to drug instrumentalization as a two-step behavioral process: (1) the seeking and consumption of a psychoactive drug in order to change the present mental state into a previously learned mental state, which then allows for (2) better performance of other, previously established behaviors and better goal achievement.

An instrument may be defined as something that helps to achieve a goal that would not be achievable or which would require a higher workload without the use of the instrument. As such, behavior itself can be an elaborate instrument (Frolov & Pavlova Reference Frolov and Pavlova2003; Skinner Reference Skinner1938). A goal is referred to here as the outcome of an already established behavior. If a behavioral goal is, for example, to socialize and to maintain a social network, instrumental behaviors would be seeking a place where other people are to be found and starting social interaction with them.

How can a psychoactive drug be considered an “instrument”? The instrument is, in this case, the effect of the drug on the organism's mental state. The nervous system of human beings and other vertebrates displays different modes of action, which can be referred to as mental states (also termed internal or affective states). Mental states are the brain's working modes that are held stable over longer periods of time (minutes to hours) during which they provide the functional setting for fast computational processes in the millisecond-to-minutes range. Mental states govern an organism's subjective perception, memory retrieval, and autonomic and behavioral responses (White Reference White1996). It is suggested that the brain's mental states are determined by the different functional states of the modulatory transmitter systems, such as the dopaminergic, serotonergic (5-HT), acetylcholinergic (ACh), noradrenergic (NA), and various neuropeptidergic systems, which control the information processing in diencephalic and telencephalic target regions of the brain (Castren Reference Castren2005). These systems display different modes of basal activity depending on various external factors, such as time of day, season, or environment, as well as on various internal factors, such as glucose, oxygen, or hormone levels in the blood (e.g., Aston-Jones et al. Reference Aston-Jones, Rajkowski and Cohen1999; Jacobs & Fornal Reference Jacobs, Fornal, Müller and Jacobs2010; Sarter & Bruno Reference Sarter and Bruno1997; Schultz Reference Schultz2000; Steriade et al. Reference Steriade, Datta, Pare, Oakson and Curro Dossi1990). Under different tonic activity modes, environmental stimuli can elicit very different phasic responses. Tonic, as well as stimulation-dependent phasic, responses determine stimulus processing and behavioral responses generated by the brain.

These mental states predispose an organism's responses to the options that its environment offers. These responses, in turn, determine an organism's success in performing previously established instrumental behaviors and, hence, how effectively the organism can reach its goals. As such, an organism's mental state essentially determines if a previously established behavior will be performed to reach a certain goal. Furthermore, if an organism pursues a goal, there is a particular mental state that allows the organism to most effectively perform the behavior with respect to the outcome. For example, if the goal is to get from place A to B by the behavior “driving a car,” an organism can perform this action best in an attentive mental state and less well in a tired and distracted state.

By definition, all psychoactive drugs change an organism's mental state (e.g., Fischman & Schuster Reference Fischman and Schuster1982; Post et al. Reference Post, Kotin and Goodwin1974). However, this would be a trivial explanation for drug-taking behavior and does not acknowledge the full extent of the behavioral complex involved in non-addictive drug consumption. Here, we argue that the set of the organism, the surrounding settings, and the subsequent behaviors that follow the change in mental state are pivotal (Zinberg Reference Zinberg1984) for a full appreciation of drug seeking and consumption, and the resulting mental state change. On the one hand, drug consumption arises in a particular environment and in particular mental states. Drug-unrelated behaviors are performed, however, when the drug is on board and the drug-induced change in mental state is in full swing. These behaviors can be viewed as drug-independent, in that they were established independently from drug use and could be performed without anteceding drug use and mental state change. For example, most adults can drive a car from A to B undrugged. After a long working day, however, having a last coffee and a subsequently “refreshed” and attentive mind may enable the driver to better drive home. In this example, the effects of caffeine on the mental state are the instrument. The A process of psychoactive drug instrumentalization would be the “coffee preparing and drinking,” whereas the B process would be “driving the car.” The individual instrumentalization goal would be “driving home,” which might belong to the goal class of “improving cognitive performance and counteracting fatigue.” A superior goal achievement would outweigh the additional effort of seeking and consuming a psychoactive drug before performing the behavior, for example, an instrumental behavior (Heyman Reference Heyman1996).

4. Psychoactive drug use from an evolutionary perspective

In an evolutionary approach to non-addictive psychoactive drug consumption, we discuss the evidence for “drug instrumentalization” at four different levels of behavioral analysis: (1) its evolutionary history, (2) in its adaptive function for reproduction and survival, (3) the proximate causation of the behavior, and (4) the ontogeny of the behavior – that is, its development in the life history of a single individual (Hill & Newlin Reference Hill and Newlin2002; Nesse Reference Nesse2002; Tinbergen Reference Tinbergen1963). A distinct behavior, to be acknowledged as a true adaptation, needs to solve an adaptational problem that would not be solved by chance without specific selection pressure (Miller Reference Miller2000). Is there any adaptational problem to which drug consumption could reasonably offer a solution? We suggest that the adaptational problem is the occurrence of multiple distinct microenvironments for single individuals who must make fast transitions among those microenvironments (Bronfenbrenner Reference Bronfenbrenner1994).

Microadaptations as specific adaptations to each microenvironment may be supported best by behaviors that are under opposing selection pressures (Cosmides & Tooby Reference Cosmides, Tooby, Hirschfeld and Gelman1994; Crawford Reference Crawford2000). Static behavioral traits that are constant over a developmental period, or even over the whole life span, may appear as less advantageous than a mechanism that allows flexibly adjusting behavioral traits according to each microenvironment (Cosmides & Tooby Reference Cosmides, Tooby, Hirschfeld and Gelman1994; Tooby & Cosmides Reference Tooby, Cosmides, Barkow, Cosmides and Tooby1992). An example for this may be “social disinhibition” as a behavioral trait in humans. Although certainly appropriate and rewarded in a close social setting, it is inappropriate and even punished in a professional work environment. An adaptation to flexibly shift between enhanced and suppressed “social disinhibition” when changing microenvironments may provide an optimal net adaptation.

4.1. The ultimate cause of psychoactive drug use

Evolutionary psychologists suggest that many of our current behaviors can be viewed as adaptations to our ancestral environment. Furthermore, these historical adaptations should have solved a problem ultimately enhancing lifetime reproduction of self or kin (Cosmides & Tooby Reference Cosmides, Tooby, Hirschfeld and Gelman1994; Reference Cosmides and Tooby1999). The consumption of psychoactive plants has occurred for at least 10,000 years, according to oldest human records (Abel 1980; Dudley Reference Dudley2002; Heath Reference Heath2000; Seefelder Reference Seefelder1996; Streatfeild Reference Streatfeild2001). One origin of psychoactive drug instrumentalization may be found in the selective acquisition and preparation of food. The selective consumption of psychoactive compounds may be based on selective food seeking and consumption behavior and its flexible modification by psychological learning processes (Dudley Reference Dudley2000; Lozano Reference Lozano1998). Seeking and consumption of a particular type of food can be very specific depending on nutritional needs. Phylogenetically old learning mechanisms associate sensory parameters such as taste and visual cues of foods with their ingredients and physiological effects. The lack of a particular nutrient can trigger a focused search and consummatory behavior for a particular type of food. Based on whether the consumption maintained or failed to maintain homeostasis, this particular food will either be searched out and consumed in the future or avoided (Johnson et al. Reference Johnson, Beaton and Hall1975, Lozano Reference Lozano1998; Rozin & Kalat Reference Rozin and Kalat1971).

Ethological research in chimpanzees has shown that the choice of food may be guided not only by the nutrient content, but also by non-nutritional properties of plant compounds, in particular secondary plant metabolites (Robles et al. Reference Robles, Aregullin, West and Rodriguez1995). Wild chimpanzees selectively consume plants to self-medicate for infections, gastrointestinal problems, and other physically stressful conditions (Glander Reference Glander and Etkin1994; Page et al. Reference Page, Balza, Nishida and Towers1992; Rodriguez et al. Reference Rodriguez, Aregullin, Nishida, Uehara, Wrangham, Abramowski, Finlayson and Towers1985; Wrangham & Nishida Reference Wrangham and Nishida1983), referred to as ‘“zoopharmacognosis” (Huffman Reference Huffman2003; Rodriguez & Wrangham Reference Rodriguez and Wrangham1993). Zoopharmacognosis appears to be learned as much as food preference or avoidance (Lozano Reference Lozano1998). Depending on the physical state of the body, self-medication can be a conditional behavior in mammals – that is, consuming a particular food only when stressed, but less in recovery (Lisonbee et al. Reference Lisonbee, Villalba, Provenza and Hall2009; Villalba et al. Reference Villalba, Provenza, Hall and Lisonbee2010). Consummatory choices are made either as a prophylactic/preventive self-medication, which reduces the risk of physical distress, or as therapeutic/curative self-medication, which may reduce the physical stress once it occurred (Kester & Barbosa Reference Kester and Barbosa1994; Hagen et al. Reference Hagen, Sullivan, Schmidt, Morris, Kempter and Hammerstein2009; Singer et al. Reference Singer, Mace and Bernays2009; Sullivan et al. Reference Sullivan, Hagen and Hammerstein2008). The ability to dynamically adapt food choice according to the organism's physical state based on a learning mechanism may hence be a basic adaptive trait in mammals, enhancing survival and reproduction (Clayton & Wolfe Reference Clayton and Wolfe1993; Hagen et al. Reference Hagen, Sullivan, Schmidt, Morris, Kempter and Hammerstein2009; Sullivan et al. Reference Sullivan, Hagen and Hammerstein2008). We speculate that those learning systems, which can dynamically adapt individual food choice for nutritional needs and self-medication, are the same as those involved in choosing food to change mental state.

We also suggest that two major changes between our ancestral environment and modern environments have taken place, and these changes are crucial for understanding current drug-taking behavior (Lende Reference Lende, Wenda Trevathan, Smith and McKenna2007):

  1. 1. Only recently, with the isolation and purification of natural compounds and with the advent of synthetic chemistry, psychoactive drugs became available in pure (e.g., cocaine, amphetamine) or highly concentrated form (e.g., alcohol). For other drugs, selective breeding of the crops increased their drug content significantly (e.g., Δ9-THC in cannabis plants). Recently available purified psychoactive substances may represent a new “niche” we have constructed; and this niche has the potential to modify the future basis of natural selection (Laland et al. Reference Laland, Odling-Smee and Feldman2000; Reference Laland, Odling-Smee and Myles2010). Psychoactive drug consumption is now considered a polygenetically determined behavior (Stacey et al. Reference Stacey, Clarke and Schumann2009) influenced by environment and culture (Blomeyer et al. Reference Blomeyer, Treutlein, Esser, Schmidt, Schumann and Laucht2008; Clarke & Schumann Reference Clarke and Schumann2009; Laland et al. Reference Laland, Odling-Smee and Myles2010). The availability of purified psychoactive substances is now part of the environment in many societies (Lende Reference Lende, Wenda Trevathan, Smith and McKenna2007), which may then interact with a genetically determined predisposition for drug use and drug addiction (Bierut et al. Reference Bierut, Dinwiddie, Begleiter, Crowe, Hesselbrock, Nurnberger, Porjesz, Schuckit and Reich1998; Kendler et al. Reference Kendler, Prescott, Myers and Neale2003a; Reference Kendler, Jacobson, Prescott and Neale2003b; Schumann Reference Schumann2007).

    Psychoactive drug seeking and consumption can be observed in fruit flies (Devineni & Heberlein Reference Devineni and Heberlein2009), rodents (Arroyo et al. Reference Arroyo, Markou, Robbins and Everitt1998; Witkin et al. Reference Witkin, Savtchenko, Mashkovsky, Beekman, Munzar, Gasior, Goldberg, Ungard, Kim, Shippenberg and Chefer1999; Yokel & Pickens Reference Yokel and Pickens1973), dogs (Risner & Jones Reference Risner and Jones1980), and monkeys (Fantegrossi et al. Reference Fantegrossi, Woolverton, Kilbourn, Sherman, Yuan, Hatzidimitriou, Ricaurte, Woods and Winger2004; Howell & Byrd Reference Howell and Byrd1995; Johanson et al. Reference Johanson, Balster and Bonese1976; Ritz & Kuhar Reference Ritz and Kuhar1989) when given access to a drug. Although the availability of purified psychoactive drugs is a new environmental feature (Nesse Reference Nesse2002), the behavioral capacity to consume drugs – the learning mechanisms – developed much earlier in evolution.

  2. 2. In industrialized societies, an individual's workload is so high that a person may need to perform many different behaviors with contrasting types of effort. It is speculative whether single behaviors need to be performed with more effort now than in the past when considering available resources (there are more tools now) and relative outcomes (tool-supported behaviors are usually more effective). One may, nevertheless, reasonably guess that the modern environment contains more and stronger differentiated microenvironments. This may become evident, for example, by the availability of technical tools that can now be very specific for a microenvironment and yet require a high degree of training and effort in their use (e.g., a computer for work or a bicycle for spare time). We can also guess that transitions between these settings occur at a much faster rate than they did for our pre-agricultural ancestors. This may put a selection pressure not only on single behaviors, but even more on behavioral flexibility – that is, the transition from one behavior to another.

We suggest that non-addictive psychoactive drug instrumentalization helps to solve an adaptational problem, employing species-general learning mechanisms that dynamically adapt the search for and consumption of plants and plant compounds. In a modern environment, however, the problem changed together with the emergence of supportive ‘“instruments.” As for many functional adaptations (Cosmides & Tooby Reference Cosmides and Tooby1999; Wakefield Reference Wakefield1999), psychoactive drug use behavior may, under these relatively recently occurring environmental changes, have led a minority of individuals to evolutionary dysfunctional behaviors, one of which is drug addiction (American Psychiatric Association 1994).

4.2. Proximate mechanisms of psychoactive drug use

A consideration of the evolution of psychoactive drug consumption suggests a number of different proximate mechanisms that provide unique adaptations to particular microenvironments (Lende Reference Lende, Wenda Trevathan, Smith and McKenna2007). An organism's environment can therefore be considered the sum of its microenvironments (Bronfenbrenner Reference Bronfenbrenner1994), in which distinct behavioral flexibility is the best adaptation. Each of these behaviors may be seen as a microadaptation. In fast-changing microenvironments, short transition times between mental states may be advantageous because they allow behavioral flexibility. We suggest the proximate adaptive problem that may be solved by psychoactive drug use is (a) to facilitate the transition between different mental states and (b) to enhance the magnitude or duration – or both – of an ongoing mental state.

This generally stated hypothesis can be quickly made empirical by asking non-addicts why and under which circumstances they consume psychoactive drugs. Epidemiological data indicate that people give a wide range of different answers on the question why they consume psychoactive drugs (e.g., Brown Reference Brown1985; Brown et al. Reference Brown, Goldman, Inn and Anderson1980; Cooper et al. Reference Cooper, Frone, Russell and Mudar1995; Maloff et al. Reference Maloff, Becker, Fonaroff, Rodin, Zinberg and Harding1981). Baum-Baicker (Reference Baum-Baicker1985) has summarized five areas of benefit for alcohol consumption: (1) stress reduction, (2) mood enhancement, (3) cognitive performance, (4) reduced clinical symptoms of depression, and (5) improved function in the elderly. Reviews of the growing experimental evidence by Chick (Reference Chick1999), Heath (Reference Heath2000), and Peele and Brodsky (Reference Peele and Brodsky2000) and a functional analysis of methamphetamine use by Lende et al. (Reference Lende, Leonard, Sterk and Elifson2007) confirmed these earlier observations. Of course, not all motivations for consumption are consciously accessible and reportable (Davies Reference Davies1997; O'Brien et al. Reference O'Brien, Childress, Ehrman and Robbins1998; Skog Reference Skog2000). Overall, these themes of drug consumption may ultimately serve efforts directed to reproduction or efforts directed toward one's own survival. Therefore, psychoactive drug use should, like any important human behavior, be considered with regard to these two life themes raised by behavioral ecologists when considering the continuous trade-off between allocations of finite human resources (Hill & Chow Reference Hill and Chow2002).

In the following paragraphs, we describe different proximal mechanisms of psychoactive drug use in terms of unique instrumentalization goals. Their general functions for reproduction or survival and maintenance (or both) are discussed. To substantiate these views, we suggest plausible neuropharmacological mechanisms for improved functioning.

4.2.1. Improved social interaction

The establishment and maintenance of social groups and networks is essential for many species (Axelrod & Hamilton Reference Axelrod and Hamilton1981; Hamilton Reference Hamilton1964). For obligatorily social animals, including humans, social interaction becomes an incentive by itself (e.g., Matthews et al. Reference Matthews, Abdelbaky and Pfaff2005; Panksepp & Lahvis Reference Panksepp and Lahvis2007). In modern societies, most adults spend a great deal of their time in training- or work-related microenvironments. A large body of explicit and implicit rules governs interactions between people in these microenvironments. Although social encounters are manifold, private social interactions are systematically suppressed in order to enhance work performance. Professional interactions require a high degree of attention and cognitive effort, as well as a suppression of overt emotional responses. These microenvironments appear to make the establishment of social bonds deliberately difficult. The formation of social bonds is rather facilitated by a state of emotional openness and accessibility and some display of private individuality. Transitory periods between professional and private microenvironments, such as after-school or after-work gatherings or activities, are where peer groups and social networks are formed and maintained.

Interestingly, a number of drugs change mental states in a way that appears to facilitate the transition from a professional to a private behavioral repertoire. It is important to note that it is not the pharmacological effect of the drug alone that enhances social behavior; rather, it is the interaction with the social environment. In a drug-free state, social settings alone induce social behavior, but perhaps less effectively and more briefly.

Psychoactive drugs that can facilitate social behavior under various circumstances are alcohol (Bradizza et al. Reference Bradizza, Reifman and Barnes1999; Glynn et al. Reference Glynn, LoCastro, Hermos and Bosse1983; Kuntsche et al. Reference Kuntsche, Knibbe, Gmel and Engels2005), marijuana (Bonn-Miller et al. Reference Bonn-Miller, Zvolensky and Bernstein2007; Zvolensky et al. Reference Zvolensky, Vujanovic, Bernstein, Bonn-Miller, Marshall and Leyro2007), cocaine (Lende Reference Lende2005; O'Malley et al. Reference O'Malley, Johnston and Bachman1985), and other psychostimulants (Davey et al. Reference Davey, Richards and Freeman2007; O'Malley et al. Reference O'Malley, Johnston and Bachman1985), when used in a low- to medium-dose range (Boys & Marsden Reference Boys and Marsden2003; Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001; Cato Reference Cato1992; Segal Reference Segal1985; Simons et al. Reference Simons, Correia and Carey2000). Also, some effects of nicotine and caffeine may be useful to maintain social interactions (Cauli & Morelli Reference Cauli and Morelli2005; Eissenberg & Balster Reference Eissenberg and Balster2000).

Alcohol reduces social inhibition, discomfort in social situations, and social anxiety; increases talkativeness; and increases the tendency to talk about private affairs (Baum-Baicker Reference Baum-Baicker1985; Booth & Hasking Reference Booth and Hasking2009; Carrigan et al. Reference Carrigan, Ham, Thomas and Randall2008; Peele & Brodsky Reference Peele and Brodsky2000). These “beneficial effects” are brought about by the multiple pharmacological targets of alcohol in the brain (Harris et al. Reference Harris, Trudell and Mihic2008; McBride et al. Reference McBride, Le and Noronha2002; Spanagel Reference Spanagel2009; Tupala & Tiihonen Reference Tupala and Tiihonen2004). Most important for these effects is probably the interaction of alcohol with GABAA-receptors in the brain. γ-Aminobutyric acid (GABA) is the most abundant inhibitory transmitter in the brain (Feldman et al. Reference Feldman, Meyer and Quenzer1997). Alcohol at low to medium doses enhances GABAergic activity, leading to reduced anxiety levels and a behavioral disinhibition. An indirect neurochemical effect of alcohol is to increase dopamine (DA) levels in the nucleus accumbens (NAc; Di Chiara & Imperato Reference Di Chiara and Imperato1988). This neurochemical effect was shown to reduce the brain's reward threshold (Koob et al. Reference Koob, Sanna and Bloom1998) and, thus, may enhance the incentive value of social interaction (Ikemoto & Panksepp Reference Ikemoto and Panksepp1999). No claim is made here that each and every effect of alcohol on the nervous system is beneficial for social interaction. For example, alcohol affects pharmacological targets in subcortical brain regions, shown to be involved in social bonding or social recognition (Ross & Young Reference Ross and Young2009). Social cognition, in contrast, involves also cortical networks, including the medial prefrontal cortex and anterior cingulate cortex (Burnett et al. Reference Burnett, Sebastian, Cohen and Blakemore2010). Although the disinhibitory effects of alcohol mediated at subcortical level may facilitate social behavior, alcohol effects at the cortical level may at the same time have no effect or even impair social cognition (Uekermann & Daum Reference Uekermann and Daum2008). We suggest that it is the sum of alcohol effects on social behavior that requires investigation.

Psychostimulant drugs, such as cocaine, amphetamine, methylphenidate, methamphetamine, and methylenedioxymethamphetamine (ecstasy, MDMA), are also used in a social context with enhanced self-exposure, such as at parties or in club settings (Britt & McCance-Katz Reference Britt and McCance-Katz2005; White et al. Reference White, Becker-Blease and Grace-Bishop2006). In addition to being more generally aroused and having increased attention, people become more talkative, disinhibited, and self-confident after consuming these drugs. In addition, psychostimulants suppress fatigue, which also enables prolonged social interaction (Fischman & Schuster Reference Fischman and Schuster1980). An increase in aggression after psychostimulant consumption (Emley & Hutchinson Reference Emley and Hutchinson1983) may result in dominating social gatherings and the “competition” for partners, further enhancing the beneficial effects for the individual (King et al. Reference King, Johnson and Van Vugt2009). Psychostimulant drugs increase extracellular activity of DA, 5-HT, and noradrenaline (NA) in the CNS by their interaction with the monoamine transporters (Ritz & Kuhar Reference Ritz and Kuhar1989; Ritz et al. Reference Ritz, Cone and Kuhar1990). They block or reverse monoamine transport (Green et al. Reference Green, Mechan, Elliott, O'Shea and Colado2003; Johanson & Fischman Reference Johanson and Fischman1989; Müller et al. Reference Müller, Carey, Huston and De Souza Silva2007a; Pum et al. Reference Pum, Carey, Huston and Müller2007; Seiden et al. Reference Seiden, Sabol and Ricaurte1993). Although high NA levels may account for the suppression of fatigue (Aston-Jones et al. Reference Aston-Jones, Rajkowski and Cohen1999), 5-HT may mediate the anxiolytic (Ho et al. Reference Ho, Pawlak, Guo and Schwarting2004; Müller et al. Reference Müller, Carey, Wilkisz, Schwenzner, Jocham, Huston and De Souza Silva2008; Schwarting et al. Reference Schwarting, Thiel, Müller and Huston1998) and aggression-enhancing effects of these drugs (Licata et al. Reference Licata, Taylor, Berman and Cranston1993; Quadros et al. Reference Quadros, Takahashi, Miczek, Müller and Jacobs2010).

Also, various dissociative anesthetic drugs, such as phencyclidine (PCP), ketamine, and γ-hydroxybutyrate (GHB), can at low doses stimulate social interactions. They can induce a feeling of empathy, reduce anxiety, and increase relaxation. At the same dose range, they are locomotor stimulants. These drugs are noncompetitive glutamate N-methyl-D-aspartate (NMDA)-receptor antagonists (Jentsch & Roth Reference Jentsch and Roth1999). Glutamate is the most abundant excitatory transmitter in the brain (Feldman et al. Reference Feldman, Meyer and Quenzer1997). Blocking NMDA receptors is considered the predominant mechanism for the observed behavioral effects (Britt & McCance-Katz Reference Britt and McCance-Katz2005; Weir Reference Weir2000; Wolff & Winstock Reference Wolff and Winstock2006).

A number of psychoactive drugs can be used to change an individual's mental state in ways to facilitate social interactions. A state in which conditioned and unconditioned anxiety and behavioral suppression are attenuated can be achieved by enhancing GABAergic inhibition and reducing glutamatergic excitation. Alternatively, a state in which the energization of social interaction is required can be achieved by enhancing monoaminergic modulatory transmission. Exaggerated drug use for this instrumentalization goal, however, may result in more pronounced euphoria or high effects, which may facilitate the transition to habitual drug use and addiction (e.g., Chen & Anthony Reference Chen and Anthony2004; Wagner & Anthony Reference Wagner and Anthony2002). An acute overdose reverses the sought effects and may even result in a schizophrenia-like psychotic state for psychostimulants or hallucinations and delirium for alcohol (e.g., Rich & Singer Reference Rich and Singer1991; Siegel Reference Siegel1978).

4.2.2. Facilitated sexual behavior

Closely related to an instrumentalization of psychotropic drug effects for social interaction is their use to facilitate the possibility of sexual behavior (Cooper Reference Cooper2006; Patrick & Maggs Reference Patrick and Maggs2009; Taylor et al. Reference Taylor, Fulop and Green1999). Sexual behavior may still be considered the sine qua non of natural selection. However, many of the same rules that control social interactions in society also restrict occasions for sexual behavior. A “scheduled” and time-dependent (e.g., Saturday night; Patrick & Maggs Reference Patrick and Maggs2009) transition from professional to private microenvironments may therefore significantly enhance the chances of finding a partner or allow already formed couples to escape daily routines. It may, therefore, not be a surprise that drugs that can be instrumentalized to improve social interactions also serve well for sexual behavior.

An important variable determining reproductive success and social behavior in humans is personality (Alvergne et al. Reference Alvergne, Jokela and Lummaa2010). Certain personality traits, such as introversion, may be disadvantageous in some settings but advantageous in others. Because it is argued that psychoactive drugs change mental states, one might view drug instrumentalization also as a self-induced, time-restricted personality change. For example, extroversion may change the likelihood of sexual behavior. The ability of a controlled personality trait change in a certain context may, therefore, help to improve sexual behaviors by overcoming the disadvantages of certain personality traits (e.g., Booth & Hasking Reference Booth and Hasking2009).

In support of popular belief, there is strong evidence for an association among alcohol drinking, drunkenness, and the likelihood for sexual intercourse, in particular in adolescents and young adults (e.g., Lavikainen et al. Reference Lavikainen, Lintonen and Kosunen2009; Patrick & Maggs Reference Patrick and Maggs2009; Sen Reference Sen2002; Wells et al. Reference Wells, Kelly, Golub, Grov and Parsons2010). In addition to the pharmacological effects of alcohol, the expected (conditioned) disinhibitory effects mediate the higher chances of sexual intercourse (Cooper Reference Cooper2006; Crowe & George Reference Crowe and George1989; Patrick & Maggs Reference Patrick and Maggs2009) and may predict future alcohol use (Mooney Reference Mooney1995). Cooper (Reference Cooper2006) suggested that those expectations may even be “instrumental in setting up situations that may lead to alcohol-related disinhibition of sex.” Behavioral disinhibition may also result from diminished cognitive abilities and a narrowed range of perception focusing in a “myopic” way on highly salient stimuli that can drive sexual arousal (Steele & Josephs Reference Steele and Josephs1990). We do not know if situational alcohol consumption in any way improves contemporary “reproductive success,” but this would be an interesting opportunity to distinguish perceived from actual success in the realm of sexual interaction.

As before, psychostimulant drugs may have mixed effects, serving to improve chances for sexual behavior, but may later interfere with physical performance during sexual intercourse in males (Maier Reference Maier1926; Waldorf et al. Reference Waldorf, Reinarman and Murphy1991). In particular, the elevated DA levels in the mesolimbic system may contribute to a mental state that makes the individual respond more effectively to sexual cues, making a potential partner appear more “attractive” (Ikemoto & Panksepp Reference Ikemoto and Panksepp1999; Koob et al. Reference Koob, Sanna and Bloom1998).

One often reported function of drug use is to “enhance sex.” Drugs frequently reported to be used for this purpose are alcohol, cannabis, amphetamines, ecstasy, and cocaine (Boys & Marsden Reference Boys and Marsden2003; Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001; Maier Reference Maier1926). Although mating behavior can be conceptualized as a flexible approach behavior, sexual intercourse, in contrast, is a consummatory behavior, which is controlled by other neuronal mechanisms (Ikemoto & Panksepp Reference Ikemoto and Panksepp1999). The verbal reports on enhanced pleasure taken from sexual intercourse after psychoactive drug consumption may, therefore, be based on mechanisms that enhance incentive salience.

Altogether, psychoactive drugs facilitate sexual behavior, even enhancing pleasure during sexual intercourse. The mental state they induce is for several drug classes similar to that serving social interaction. Hence, it may be assumed that neuronal mechanisms of this drug instrumentalization are largely overlapping with those facilitating social behavior.

4.2.3. Improved cognitive performance and counteracting fatigue

Highly developed societies put a high cognitive demand on individuals in education and work microenvironments (Arria & Wish Reference Arria and Wish2006). Long working hours lead to fatigue and to decline in cognitive performance. Having the means to “artificially” prolong full cognitive capacity may consequently appear to be beneficial for the individual by increasing external resources for reproduction of self or kin (e.g., money). Although little is known about whether any drug can actually increase cognitive performance in a healthy person with full mental capacity, there is considerable evidence suggesting that mild impairments resulting from exhaustion, fatigue, or mood swings can be compensated with psychoactive drugs (Boys & Marsden Reference Boys and Marsden2003; Lende et al. Reference Lende, Leonard, Sterk and Elifson2007). In this case, no new mental state is desirable, only maintenance of a baseline state over prolonged cognitive effort. Many psychoactive drugs, both legal and illicit in Western societies, improve cognitive performance in this case.

Caffeine, a major psychoactive ingredient of coffee, tea, chocolate, and soft drinks, is a legal drug frequently used to keep people awake. During waking periods, the brain levels of the neurotransmitter adenosine steadily increase and trigger fatigue and sleepiness (Hong et al. Reference Hong, Huang, Qu, Eguchi, Urade and Hayaishi2005; Huston et al. Reference Huston, Haas, Boix, Pfister, Decking, Schrader and Schwarting1996; Porkka-Heiskanen et al. Reference Porkka-Heiskanen, Strecker, Thakkar, Bjorkum, Greene and McCarley1997). As an antagonist at the adenosine A1 and A2A receptors, caffeine effectively blocks adenosine action in the brain (Cauli & Morelli Reference Cauli and Morelli2005). It is thought this action of caffeine is responsible for preventing fatigue and reducing the decline in cognitive performance after prolonged activity.

Another widely used legal drug is nicotine, the active compound in tobacco (Le Foll & Goldberg Reference Le Foll and Goldberg2006). Nicotine is an agonist at the nicotinic ACh-receptor (Markou Reference Markou2008). Nicotinic ACh-receptors in the brain are essentially involved in mediating the action of the neurotransmitter ACh to promote attention and to facilitate learning and memory (Blokland Reference Blokland1995; Sarter et al. Reference Sarter, Hasselmo, Bruno and Givens2005). Nicotine improves attention (Hahn et al. Reference Hahn, Shoaib and Stolerman2002; Hahn & Stolerman Reference Hahn and Stolerman2002) and cognitive performance in animals (Decker et al. Reference Decker, Brioni, Bannon and Arneric1995) and in nonsmoking humans (Rezvani & Levin Reference Rezvani and Levin2001). In human smokers, there is a decline in cognitive abilities after smoking cessation that can be reversed by nicotine administration (Mansvelder et al. Reference Mansvelder, van Aerde, Couey and Brussaard2006). Nicotine was also found to ameliorate cognitive deficits in patients with Alzheimer's disease. It can reduce the cognitive deficits induced by neuroleptic drug treatment in schizophrenic patients (Rezvani & Levin Reference Rezvani and Levin2001). The stimulation of nicotinic ACh-receptors by nicotine increases not only ACh, but also NA activity (Mitchell Reference Mitchell1993; Wonnacott Reference Wonnacott1997), which might contribute to the attention promoting effects of nicotine. Nicotinic ACh-receptors also modulate the activity of the mesolimbic DA system (Markou Reference Markou2008; McBride et al. Reference McBride, Murphy and Ikemoto1999; Wonnacott Reference Wonnacott1997), which could be one mechanism for how nicotine might increase the reinforcing value of non-drug reinforcers (Harrison et al. Reference Harrison, Gasparini and Markou2002; Kenny & Markou Reference Kenny and Markou2006) and hence support goal-directed behavior.

Psychostimulant drugs have been widely used to increase cognitive performance over long periods of time, in particular to maintain arousal and attention. Truck drivers in the United States and Australia use amphetamine and other psychostimulants to stay attentive during long driving hours (Davey et al. Reference Davey, Richards and Freeman2007; Grinspoon & Hedblom Reference Grinspoon, Hedblom and Harris2005). Students use prescription stimulants, such as methylphenidate, demethylphenidate, amphetamine, and methamphetamine, non-medically to promote concentration, to stay awake, to increase alertness, and to help with studying (Arria & Wish Reference Arria and Wish2006; Lende et al. Reference Lende, Leonard, Sterk and Elifson2007; McCabe et al. Reference McCabe, Knight, Teter and Wechsler2005; Sussman et al. Reference Sussman, Pentz, Spruijt-Metz and Miller2006; Teter et al. Reference Teter, Falone, Cranford, Boyd and McCabe2010; White et al. Reference White, Becker-Blease and Grace-Bishop2006). Psychostimulants were shown to effectively increase arousal and attention in humans for long periods of time at doses that induce only a minor and short-lasting “high” and no signs of dysphoria thereafter (Higgins et al. Reference Higgins, Bickel, Hughes, Lynn, Capeless and Fenwick1990; Stillman et al. Reference Stillman, Jones, Moore, Walker and Welm1993). In line with increased attention, improved learning and memory was shown after small doses of cocaine in occasional users (Higgins et al. Reference Higgins, Bickel, Hughes, Lynn, Capeless and Fenwick1990). Attention deficits induced by sleep-deprivation can be ameliorated by a low to medium dose of cocaine (Fischman & Schuster Reference Fischman and Schuster1980). Phasic and tonic NA activity in the brain is well known to control cognitive performance in tasks with a high attention load and potential distraction (Usher et al. Reference Usher, Cohen, Servan-Schreiber, Rajkowski and Aston-Jones1999). Cocaine and amphetamines interact with NA transporters in the brain and effectively block NA reuptake at the synapse (Ritz & Kuhar Reference Ritz and Kuhar1989; Ritz et al. Reference Ritz, Cone and Kuhar1990). This increases extracellular NA levels and causes a hyperactivation of NA receptors (Green et al. Reference Green, Mechan, Elliott, O'Shea and Colado2003; Johanson & Fischman Reference Johanson and Fischman1989; Seiden et al. Reference Seiden, Sabol and Ricaurte1993), which may account for beneficial effects of small doses of psychostimulants on cognition.

Good evidence supports the view that several psychoactive drugs are instrumentalized to enhance cognitive performance by counteracting exhaustion and fatigue. Although little enhancement can be achieved in healthy and “fresh” individuals, the decline in function during fatigue, or in several mental disorders, can be effectively overcome, if temporarily, by these drugs. Likely mechanisms of action are the blockade of adenosine A1 and A2A receptors, activation of nicotinic ACh-receptors, or the enhancement of NA activity in the brain. Exaggerated use of these drugs may acutely result in hyperarousal, restlessness, and a decline in cognitive abilities (e.g., Quednow et al. Reference Quednow, Jessen, Kuhn, Maier, Daum and Wagner2006; Reference Quednow, Kuhn, Hoppe, Westheide, Maier, Daum and Wagner2007). Long-term regular use of these drugs can induce tolerance for the cognitive effects and might lead to an escalation of consumption and to drug addiction.

4.2.4. Facilitated recovery from and coping with psychological stress

Modern societies not only request constant high cognitive and physical performance, but they also allow decreasingly little time for the individual to recover from periods of intense or high work load (Anders Reference Anders1956). This leaves the individual with the pressure of finding a fast recovery and an effective way to cope with the related psychological stress. The goal is then to change the mental state from “tired and stressed” to “fresh and relaxed” in a short period of time. Ideally, after recovery, resources are replenished and stress is under control. Using drugs to accelerate recovery and to enhance coping with stress in a “spare but limited time” microenvironment may, therefore, increase the success of many behaviors in other microenvironments (Amendt Reference Amendt2003; Baum-Baicker Reference Baum-Baicker1985; Peele & Brodsky Reference Peele and Brodsky2000; Segal Reference Segal1985).

A number of pharmacologically different drugs are instrumentalized to facilitate recovery from and coping with psychological stress. Humans as well as animals self-administer alcohol (Cooper et al. Reference Cooper, Russell and George1988; Reference Cooper, Russell, Skinner, Frone and Mudar1992; Kuntsche et al. Reference Kuntsche, Knibbe, Gmel and Engels2005), cannabis (Bonn-Miller et al. Reference Bonn-Miller, Zvolensky and Bernstein2007; Zvolensky et al. Reference Zvolensky, Vujanovic, Bernstein, Bonn-Miller, Marshall and Leyro2007), cocaine (Lende Reference Lende2005; Waldorf et al. Reference Waldorf, Reinarman and Murphy1991), methamphetamine (Lende et al. Reference Lende, Leonard, Sterk and Elifson2007), barbiturates, benzodiazepines, and other sedative anxiolytic drugs (Boyd et al. Reference Boyd, Teter, West, Morales and McCabe2009) to cope with stress (Boys & Marsden Reference Boys and Marsden2003; Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001; Bradizza et al. Reference Bradizza, Reifman and Barnes1999; De las Cuevas et al. Reference De las Cuevas, Sanz and De la Fuente2003; Griffiths et al. Reference Griffiths, Lamb, Sannerud, Ator and Brady1991; Heberlein et al. Reference Heberlein, Bleich, Kornhuber and Hillemacher2009; Lader Reference Lader1994; Perkins Reference Perkins1999; Segal Reference Segal1985). In the last decade, evidence for a survival promoting effect of moderate alcohol consumption in humans accumulated. Moderate alcohol consumption, which can be maintained with a high degree of stability, was associated with better health, more close friendships, and more family support than was total abstinence (Mondaini et al. Reference Mondaini, Cai, Gontero, Gavazzi, Lombardi, Boddi and Bartoletti2009; Peele & Brodsky Reference Peele and Brodsky2000; Rodgers et al. Reference Rodgers, Korten, Jorm, Christensen, Henderson and Jacomb2000;Skogen et al. Reference Skogen, Harvey, Henderson, Stordal and Mykletun2009; Taylor et al. Reference Taylor, Rehm and Gmel2005; but see also: Sareen et al. Reference Sareen, McWilliams, Cox and Stein2004). Moderate drinkers were also found to face less depression than abstainers in the presence of stress (Lipton Reference Lipton1994). Chronic moderate, but not high, alcohol consumption can reduce the risk of somatic diagnoses, as well as mental disorders such as anxiety and depression (Peele & Brodsky Reference Peele and Brodsky2000; Skogen et al. Reference Skogen, Harvey, Henderson, Stordal and Mykletun2009).

Alcohol inhibits excitatory glutamatergic transmission and enhances inhibitory GABAergic activity at the GABAA-receptor (Spanagel Reference Spanagel2009). Barbiturates and benzodiazepines also modulate the GABAA-receptor (Ito et al. Reference Ito, Suzuki, Wellman and Ho1996), though at other binding sites than alcohol, and allosterically enhance responses to the inhibitory transmitter GABA (Allison & Pratt Reference Allison and Pratt2003). Enhanced GABAergic activity is believed to reduce anxiety and the impact of conditioned aversive stimuli. This is one way in which these drugs may attenuate the processing of stress-related stimuli at a subconscious level. For conscious processing of stress-related stimuli, neocortical circuits, which also contain a high number of GABAA-receptors, are more likely to be involved (Feldman et al. Reference Feldman, Meyer and Quenzer1997). By their interaction with neocortical GABAA-receptors, sedative drugs can dampen cognitive activity and memory of aversive events (Curran Reference Curran1991).

The most widespread illicit psychoactive drug instrumentalized to ameliorate pressure and to reduce stress is cannabis (Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001). The main psychoactive compound of cannabis is Δ9-tetrahydrocannabinol (THC; Iversen Reference Iversen2000). THC is an exogenous ligand at the brain's cannabinoid 1 (CB1)-receptors, which among others control the emotional impact of external stimuli and thoughts (Mechoulam et al. Reference Mechoulam, Fride and Di Marzo1998). CB1-receptor activation was shown to control the extinction of aversive memories (Marsicano et al. Reference Marsicano, Wotjak, Azad, Bisogno, Rammes, Cascio, Hermann, Tang, Hofmann, Zieglgansberger, Di Marzo and Lutz2002), which might contribute to the stress ameliorating effects of THC.

Interestingly, social stress was also found to increase the self-administration of nonsedating drugs, such as cocaine in animals and humans. The drug-induced increase in arousal (Haney et al. Reference Haney, Maccari, Le, Simon and Piazza1995) might involve another coping mechanism that resembles more a “fight” than a “flight” response. Psychostimulant drugs increase aggression levels and physical strength and can suppress fatigue (Green et al. Reference Green, Mechan, Elliott, O'Shea and Colado2003; Johanson & Fischman Reference Johanson and Fischman1989; Seiden et al. Reference Seiden, Sabol and Ricaurte1993), which are useful effects for an active stress coping mechanism. However, animal studies showed that an increase in cocaine self-administration in order to cope with social stress was only observed in animals with low spontaneous activity (Kabbaj et al. Reference Kabbaj, Norton, Kollack-Walker, Watson, Robinson and Akil2001). Several findings suggest that the ways in which psychoactive drugs are instrumentalized for coping with stress may largely depend on the individual's personality traits and coping strategies.

A number of different classes of drugs can be used to facilitate recovery from and coping with stress. They can be consumed to self-induce a mental state in which conditioned and unconditioned anxiety and mental preoccupation with them are attenuated. This is predominantly achieved by enhancing GABAergic inhibitory activity or by activating cannabinoid receptors. However, an acute overdose of sedating drugs may have fatal effects (Charlson et al. Reference Charlson, Degenhardt, McLaren, Hall and Lynskey2009). For some individuals, an aroused and attentive state of mind might serve to actively cope with stress, when behavioral action is required. This is served by enhanced monoaminergic activation. Chronic exaggerated drug use for this instrumentalization goal may result in restlessness, a hyperanxious state during withdrawal, and compulsive drug use to overcome this state.

4.2.5. Self-medication for mental problems

Psychiatric or mental disorders are characterized by the prolonged persistence of a mental state that is perceived as aversive (American Psychiatric Association 1994). They can be considered as a temporary, recurrent, or continuous breakdown of the homeostatic mechanisms in the neuronal systems that determine mental states. Behavioral functions and reproduction rates are significantly impaired in these disorders (Uher Reference Uher2009).

Certain psychiatric disorders seem to correlate with an increased consumption of psychoactive drugs with a particular neurochemical profile. Although psychoactive drugs do not persistently restore homeostasis in psychiatric patients, they may cause a temporary change to a less aversive mental state. In that, they may provide at least a temporary relief from suffering and an enhanced “functioning” in everyday life (e.g., Lende et al. Reference Lende, Leonard, Sterk and Elifson2007). The self-medication might improve the adaptation to the adverse condition (Nesse & Berridge Reference Nesse and Berridge1997). This might also apply to mental states that are perceived as aversive (e.g., being in a depressed mood), but do not fulfill the diagnostic criteria of a psychiatric disease (Boys & Marsden Reference Boys and Marsden2003; Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001).

It is well known that people suffering from negative affect use psychoactive drugs to self-medicate and regain some sense of control over their mental state (Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001; Glynn et al. Reference Glynn, LoCastro, Hermos and Bosse1983; Khantzian Reference Khantzian1985; Reference Khantzian1997; Markou et al. Reference Markou, Kosten and Koob1998; Sher et al. Reference Sher, Grekin and Williams2005). Considerable evidence supports the view that alcohol is consumed to provide relief from negative affect (Peele & Brodsky Reference Peele and Brodsky2000), although it is still unclear whether this is a causal or associative relationship (Room Reference Room2000). The effectiveness of alcohol depends on several factors such as genetic predisposition, expectancies, and environmental factors (Sher et al. Reference Sher, Grekin and Williams2005).

Increased consumption of nicotine and cannabis has been demonstrated in schizophrenic individuals (Hughes et al. Reference Hughes, Hatsukami, Mitchell and Dahlgren1986). It is believed that these drugs may exacerbate positive symptoms such as hallucinations (Perry & Perry Reference Perry and Perry1995). However, the aversive negative symptoms, such as the flattening of affect, and possibly cognitive impairments, might improve with cannabis (Potvin et al. Reference Potvin, Stip and Roy2003). Nicotine might improve cognitive deficits in schizophrenic individuals with prescribed neuroleptics (Rezvani & Levin Reference Rezvani and Levin2001). At present, it can only be speculated that the nicotinic ACh-receptor activation, which enhances cognitive performance under certain circumstances in healthy subjects, might also account for the benefits in cognitively impaired schizophrenics.

THC was shown to alleviate anxious states and to reduce pain in chronic neurological disorders such as multiple sclerosis (Williamson & Evans Reference Williamson and Evans2000). There is a high rate of substance abuse in patients suffering from posttraumatic stress disorder (PTSD) to self-medicate the PTSD symptoms (Jacobsen et al. Reference Jacobsen, Southwick and Kosten2001). Benzodiazepines are used to self-medicate other forms of anxiety disorders and sleep-disturbances off prescription (Heberlein et al. Reference Heberlein, Bleich, Kornhuber and Hillemacher2009). Opiate drugs were reported to be used by people who suffer from physical pain (Boyd et al. Reference Boyd, McCabe, Cranford and Young2006; McCabe et al. Reference McCabe, Cranford, Boyd and Teter2007b; Zacny & Lichtor Reference Zacny and Lichtor2008). People with tendencies for rage and strong violence reported opiate use because they felt that the drug effects help to control the outbursts (Khantzian Reference Khantzian1985; Reference Khantzian1997).

This instrumentalization goal might also explain why non–clinically diagnosed people use psychostimulant drugs to deal with the distress caused by their depression, dysphoria, hypomania, hyperactivity, and attention-deficit problems (Khantzian Reference Khantzian1985; Reference Khantzian1997; Lende et al. Reference Lende, Leonard, Sterk and Elifson2007; Teter et al. Reference Teter, Falone, Cranford, Boyd and McCabe2010). It was suggested that some biomarkers of depression resemble those of drug withdrawal, such as a chronic down-regulation in the activity of the DA- and 5-HT-systems (Maisonneuve et al. Reference Maisonneuve, Ho and Kreek1995; Wyatt et al. Reference Wyatt, Karoum, Suddath and Fawcett1988). Drug use could possibly restore homeostasis and ameliorate depressive symptoms (Markou et al. Reference Markou, Kosten and Koob1998). Nevertheless, attempted self-medication may increase the risk of disease progression in the long run (McLellan et al. Reference McLellan, Woody and O'Brien1979; Weiss et al. Reference Weiss, Mirin, Michael and Sollogub1986).

Sullivan and Hagen (Reference Sullivan and Hagen2002) suggested that at least part of the motivation to use psychoactive drugs for self-medication might be a neurotransmitter deficit in the brain, leading to psychiatric diseases. Indeed, a reduction in DA- and 5-HT transmission can dramatically reduce behavioral activity and incentive motivation (Carey et al. Reference Carey, DePalma, Damianopoulos, Hopkins, Shanahan, Müller and Huston2004; Reference Carey, Huston and Müller2008). Several psychoactive plant compounds resemble structural motifs of those key neurotransmitters that are known to be involved in psychiatric diseases. Sullivan and Hagen (Reference Sullivan and Hagen2002) argued that the drug might compensate for the deficit. This might be true for some drugs. For example, people suffering from depression use cocaine as a preferred drug to ameliorate a negative affective state (Khantzian Reference Khantzian1985; Reference Khantzian1997). Depression is associated with disturbed 5-HT activity (Carr & Lucki Reference Carr, Lucki, Müller and Jacobs2010). Acute administration of cocaine, as well as synthetic antidepressant drugs, increases 5-HT levels (Müller et al. Reference Müller, Thönnessen, Barros, Tomaz, Carey and Huston2004; Reference Müller, Carey, Huston and De Souza Silva2007a; Reference Müller, De Souza Silva and Huston2007b). For the long-term antidepressant effects, however, chronic drug taking is required to increase basal 5-HT levels and 5-HT throughput (Carr & Lucki Reference Carr, Lucki, Müller and Jacobs2010).

An altered mental state and inadequate behavioral responses characterize psychiatric disorders. Several psychotropic drugs were found to be useful by individuals to temporarily ameliorate at least part of their disease-related mental or/and cognitive disturbances. Because disease etiology for major psychiatric disorders is still little understood, it appears difficult to identify those pharmacological actions of the drugs that might serve this instrumentalization goal. Exaggerated drug use for this goal, however, was often found to potentiate disease symptoms in the long term and might add a comorbid addiction to the original disorder (Robbins & Everitt Reference Robbins and Everitt1999).

4.2.6. Sensory curiosity – Expanded perception horizon

Novel stimuli and novel environments carry the potential of new reward contingencies that would allow for the establishment of new behaviors that can lead to a higher overall “reward income” for an individual. The greater the number of distinct behaviors leading to rewards that are established, the more independent an individual will become from changes in the environment when single stimulus-behavior-reward associations lose their contingency. As such, the non–drug related search for novelty and new environments is a driving force to expose an individual to stimuli and environments where new stimulus-reward contingencies exist and can be learned (Kelley et al. Reference Kelley, Cador, Stinus, Boulton, Baker and Greenshaw1990; Thiel et al. Reference Thiel, Müller, Huston and Schwarting1999).

At least in humans, insight may not only be gained by de novo experience of the external world, but also by restructuring of knowledge already gained. As such, a qualitatively or quantitatively altered cognitive performance (Lende et al. Reference Lende, Leonard, Sterk and Elifson2007; Stillman et al. Reference Stillman, Jones, Moore, Walker and Welm1993) may also count as an example of novelty. Although the first is associated with learning and the formation of new representations (McGaugh Reference McGaugh2000; Kandel Reference Kandel2001), the later may involve the coincident activation of previously unrelated representations that are then interlinked. Novelty and new sensations can be considered as primary reinforcers in humans and animals (Weil Reference Weil1998; Zuckerman Reference Zuckerman1990). They were shown to increase DA activity in the mesolimbic system of the brain in a similar way to other primary reinforcers (Feenstra et al. Reference Feenstra, Botterblom and Vanuum1995; Martel & Fantino Reference Martel and Fantino1996). The active enhancement of this exposure may contribute to reward learning as a major behavioral adaptation that enhances an organism's survival chances and reproduction.

Psychoactive drugs, by definition, change mental states. This constitutes a novelty effect on the first consumption episodes for each drug. It is unique to particular substances and is reflected in a drug's discriminative stimulus properties (Overton Reference Overton1968; Stolerman Reference Stolerman1992). It is believed that the distinct pharmacological profile of each drug results in unique discriminative stimulus properties. After repeated exposure, the discriminative stimulus properties still exist, but they are not novel anymore, and something other than the novelty effects are needed to motivate continuation of drug use. If no other motives or instrumentalization goals arise, the “experimental” consumption of the drug may cease. This is supported by drug consumption surveys that collectively show considerably higher rates for trying a particular drug once in a lifetime versus regular consumption, measured as, for example, monthly use (SAMHSA 2005; EMCDDA 2009).

From consumer reports, it can be inferred that some psychoactive drugs may not provide a completely new sensory stimulus or environment but rather change an organism's mental state such that present stimuli or already established memories thereof are perceived and dealt with in a new fashion, including self-perception (Weil Reference Weil1998). However, the psychotropic drug–induced changes in the perception of the external and internal world do not expose the individual to new reward contingencies and may finally offer little improvement in “reward income.” It may, therefore, drive psychotropic drug consumption only for a relatively short period of time – that is, until an individual has learned that the drug-induced changes in stimulus perception are not providing new reward-contingencies. This view is in line with self-administration studies in animals. These studies showed that animals do not regularly self-administer those drugs that humans consume primarily for their sensory perception changing properties, such as hallucinogens (Nichols Reference Nichols2004).

Hallucinogenic drugs, a particular group of psychoactive drugs, are used to change sensation and perception of the external world and to increase self-understanding and self-discovery (Boys & Marsden Reference Boys and Marsden2003; Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001; Cato Reference Cato1992; Nichols Reference Nichols2004). These drugs include natural compounds, like mescaline and psilocybin, as well as semisynthetic drugs, like lysergic acid diethylamide (LSD). They induce a mental state characterized by perceptual hypersensitivity, illusions, and hallucinations. The experience of time and space and the perception of the self are changed. Highly dependent on expectations and setting, hallucinogens can produce a loss of ego boundaries with an elevated mood but may also cause psychotic ego dissolution with fear, paranoid ideation, and a split ego (Geyer & Vollenweider Reference Geyer and Vollenweider2008; Nichols Reference Nichols2004). In this state, environmental stimuli can be perceived in a new way that is reported to be an enrichment of one's perceptual world.

LSD and other hallucinogenic drugs are 5-HT2-receptor agonists, activating predominantly 5-HT2A and 5-HT2C receptors. There is now wide agreement that the effects on the 5-HT2A receptor are crucial for the hallucinogenic action (Gonzalez-Maeso & Sealfon Reference Gonzalez-Maeso and Sealfon2009; Halberstadt & Nichols Reference Halberstadt, Nichols, Müller and Jacobs2010). They also reduce 5-HT turnover and 5-HT neuronal firing in the raphe nuclei. This suggests a further enhancement of the contrast in activation between 5-HT2A/2C and all other 5-HT receptors. 5-HT2A receptors are found in a high density in the neocortex (Mengod et al. Reference Mengod, Cortes, Teresa Vilaro, Hoyer, Müller and Jacobs2010) where they fine-tune principal- and inter-neurons (Sheldon & Aghajanian Reference Sheldon and Aghajanian1990; Aghajanian & Marek Reference Aghajanian and Marek1997). 5-HT and 5-HT2 receptors play an important role in sensory stimulus processing (Jacobs & Fornal Reference Jacobs, Fornal, Müller and Jacobs2010; Pum et al. Reference Pum, Huston, De Souza Silva and Müller2008; Quednow et al. Reference Quednow, Kuhn, Mossner, Schwab, Schuhmacher, Maier and Wagner2008; Reference Quednow, Schmechtig, Ettinger, Petrovsky, Collier, Vollenweider, Wagner and Kumari2009). The artificial disturbance of this fine-tuning leads to an altered mental state that is relatively selective for the processing of the physical properties of the stimulus without enhancing its incentive salience. However, an interaction of subcortical 5-HT2 receptors, e.g., with the mesolimbic DA system may also affect the emotional properties of a stimulus resulting in, e.g., “horror trips.” Although 5-HT2A and 5-HT2C receptors control DA activity at the level of mesocorticolimbic DA systems (Adell et al. Reference Adell, Bortolozzi, Diaz-Mataix, Santana, Celada, Artigas, Müller and Jacobs2010; McMahon et al. Reference McMahon, Filip and Cunningham2001; Müller & Carey Reference Müller and Carey2006), the effects of hallucinogenic drugs are not considered to induce euphoria or have a major addictive potential (Nichols Reference Nichols2004).

A similar instrumentalization might also apply to the entactogenic drug, MDMA (Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001), which has a hallucinogenic profile and induces a unique feeling of “divine oneness” with the world. This particular effect might be mediated by an interaction with the peptide transmitter oxytocin, which facilitates social bonding and the feeling of attachment (Halberstadt & Nichols Reference Halberstadt, Nichols, Müller and Jacobs2010). MDMA increases 5-HT activity in the brain (Sprouse et al. Reference Sprouse, Bradberry, Roth and Aghajanian1990), which also hyperactivates 5-HT2A receptors. This effect was shown to be involved in the perceptual changes and emotional excitation following MDMA administration, but did not appear to contribute to the positive effects on mood (Liechti et al. Reference Liechti, Saur, Gamma, Hell and Vollenweider2000). In contrast to LSD, MDMA has a significant effect on DA and NA activity, which might motivate MDMA's use beyond the sensory curiosity.

Phencyclidine, ketamine, and gammahydroxybutyrate (GHB) are drugs used in the club and rave scenes. They are dissociative anesthetics used in the clinic. At high dose, they can have profound hallucinogenic effects. They are unique in that they induce a dissociative state, characterized by sensory deprivation, dreamlike visions, and feelings of the “self” separated from the body. Even near-death experiences were reported. In contrast to serotonergic hallucinogens, they are antagonists at the glutamate NMDA receptor. It is assumed that blocking this receptor, together with an interaction with opiate receptors and monoamine transporters, leads to a functional dissociation of thalamo-cortical and limbic stimulus processing. This was suggested to be the mechanism for the dissociation of the subjective perception from actual environment (Britt & McCance-Katz Reference Britt and McCance-Katz2005; Weir Reference Weir2000; Wolff & Winstock Reference Wolff and Winstock2006).

Also, cannabis was reported to be consumed to expand self- and environmental perception (Bonn-Miller et al. Reference Bonn-Miller, Zvolensky and Bernstein2007; Zvolensky et al. Reference Zvolensky, Vujanovic, Bernstein, Bonn-Miller, Marshall and Leyro2007). In particular, the perception of time is much slower after cannabis consumption (Iversen Reference Iversen2000). It has been speculated that activation of the CB1 receptors in the association cortices of the brain and the presynaptic inhibition of DA, NA, 5-HT, and glutamate release may mediate the changes in self- and environmental perception (Felder & Glass Reference Felder and Glass1998; Porter & Felder Reference Porter and Felder2001).

Several drugs can be used to change one's mental state such that environmental stimuli and the self are perceived in a new fashion, without significant effects on euphoria or on the incentive properties of the stimuli. This can be achieved by drugs that either directly or indirectly activate 5-HT2A receptors or by blocking NMDA receptors. Exaggerated drug use for this instrumentalization goal may result in dangerous activities and schizophrenia-like psychoses.

4.2.7. Euphoria, hedonia, and high

“Euphoria,” “happiness,” “hedonia” – all these concepts describe a more-or-less intense feeling of well-being (the terms are used here synonymously). The pursuit of euphoria, or happiness – as either a series of short-lasting feelings or as a long-lasting mental state – is probably the greatest desire in human life (Marcuse Reference Marcuse1984; Tatarkiewicz Reference Tatarkiewicz1976). Human brains work toward linking this subjective feeling with either the receipt of a primary or secondary reward or with the change in reward contingencies – when a formerly meaningless stimulus now predicts reward availability or a formerly useless behavior now yields a reward. Although the biological function of the subjective perception of euphoria is far from clear, it appears that the amount of euphoria we perceive is related to human well-being. It was argued that mood enhancement alone is a psychological benefit gained from psychoactive drug use (Lende & Smith Reference Lende and Smith2002; Peele & Brodsky Reference Peele and Brodsky2000). An enhanced mood by itself – one without an impact on physical health and behavior – however, would rather constitute a mock benefit. In this respect, the view of drugs “hijacking” the reward system was developed (Nesse & Berridge Reference Nesse and Berridge1997), which is mostly supported by psychoactive drugs with a strong euphoria component. Alternatively, an enhanced mood can be seen as one example of a mental state change, which might allow more efficient performance of many other goal-directed behaviors and, hence, enhance chances for survival and reproduction.

Psychoactive drugs such as heroin, morphine, cocaine, amphetamine, methamphetamine, methylphenidate, and MDMA can induce a potent feeling of euphoria and an emotional “high” (e.g. Javaid et al. Reference Javaid, Fischman, Schuster, Dekirmenjian and Davis1978; Resnick et al. Reference Resnick, Kestenbaum and Schwartz1977) and are used for this reason by nonaddicts (Boyd et al. Reference Boyd, McCabe, Cranford and Young2006; McCabe et al. Reference McCabe, West and Wechsler2007a; Teter et al. Reference Teter, Falone, Cranford, Boyd and McCabe2010; Zacny & Lichtor Reference Zacny and Lichtor2008). A certain degree of euphoria can also be induced by other drugs of abuse, such as alcohol, cannabis, LSD, benziodiapines, and nicotine (e.g., Boys & Marsden Reference Boys and Marsden2003; Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001; Sher et al. Reference Sher, Grekin and Williams2005). However, the latter are usually not consumed primarily for this reason. The neuronal correlate for the profound euphoria-inducing effects of psychoactive drugs was long believed to be an increase of the extracellular DA activity in the NAc. This view developed from research on the brain's reward circuitry (Olds & Milner Reference Olds and Milner1954; Wise Reference Wise1980; Reference Wise, Legg and Both1994; Reference Wise2002) supported by the hugely influential finding that drugs of abuse increase DA levels in the NAc in vivo, whereas nonabused drugs do not (Di Chiara Reference Di Chiara1995; Di Chiara & Imperato Reference Di Chiara and Imperato1988).

It is now well understood how pharmacologically different classes of drugs converge in their acute neurophysiologic effects of increasing mesolimbic DA activity (Ameri Reference Ameri1999; Di Chiara & North Reference Di Chiara and North1992; Koob Reference Koob1992; McBride et al. Reference McBride, Murphy and Ikemoto1999). Of special importance for the role of DA in these effects appeared to be the D2 receptor (Volkow et al. Reference Volkow, Wang, Fischman, Foltin, Fowler, Abumrad, Vitkun, Logan, Gatley, Pappas, Hitzemann and Shea1997), which becomes hyperactivated during acute drug exposure. In humans, drug-induced euphoria is usually more intense than naturally occurring euphoria. There subsequently appeared to be several conceptual problems with the DA hypothesis, however (Salamone Reference Salamone1996), which led to the view that DA may not code for the euphoria, but rather signal a reward-related prediction error (Hollerman & Schultz Reference Hollerman and Schultz1998; Schultz Reference Schultz2000). This is not only the case for appetitive (i.e., pleasant) stimuli, but also for aversive stimuli (Brischoux et al. Reference Brischoux, Chakraborty, Brierley and Ungless2009; Matsumoto & Hikosaka Reference Matsumoto and Hikosaka2009; Young et al. Reference Young, Joseph and Gray1993). Although these findings may have preserved an outstanding role for DA in reinforcement learning and addiction (Ikemoto & Panksepp Reference Ikemoto and Panksepp1999; Robbins & Everitt Reference Robbins and Everitt1996), they further moved reinforcement learning away from the subjective perception of euphoria.

Robinson & Berridge (Reference Robinson and Berridge1993) suggested that DA in the NAc may be the mechanism to attribute incentive salience (i.e., the “wanting”) to cues associated with either natural or pharmacological reinforcers. However, euphoria, which is most closely conceived as the “liking” of a stimulus, should be independent from its incentive salience and may be mediated by endogenous opioid- and GABAergic mechanisms (Berridge Reference Berridge1996; Berridge & Robinson Reference Berridge and Robinson2003). In their incentive-sensitization theory, Berridge and Robinson (Reference Robinson and Berridge2003) suggested that during repeated drug consumption, a sensitization of neural systems, which attribute incentive salience, occurs. This sensitization increases the “wanting” of a drug, which results in compulsive drug seeking and taking. Thereby, the problems with the original DA hypothesis gave way to an opening for a role of other neuronal adaptations beyond NAc DA (Bardo Reference Bardo1998). Currently, an involvement of many more transmitter systems and various postsynaptic mechanisms in the euphoria-inducing and reinforcing effects of psychoactive drugs is acknowledged (Everitt & Wolf Reference Everitt and Wolf2002; Heilig & Koob Reference Heilig and Koob2007; Kalivas & Volkow Reference Kalivas and Volkow2005; Koob Reference Koob1999; Müller et al. Reference Müller, Pum, Schumann, Huston, Müller and Jacobs2010; Nestler & Aghajanian Reference Nestler and Aghajanian1997; Williams & Adinoff Reference Williams and Adinoff2007).

Euphoria is probably the easiest to accept as an instrumentalization goal for psychoactive drugs. Nevertheless, euphoria is not the most predominant and sought-after effect during most psychoactive drug taking occasions in nonaddicts (for an evolutionary discussion, see: Hagen et al. Reference Hagen, Sullivan, Schmidt, Morris, Kempter and Hammerstein2009; Sullivan et al. Reference Sullivan, Hagen and Hammerstein2008). For those drugs, which are classically associated with euphoria effects, euphoria requires a considerably higher dose than the use of the drug effects for other instrumentalization goals. Nevertheless, the mental state of a mild euphoria can be useful for many other instrumentalization goals as well; for example, for social or sexual behavior. Although an involvement of NAc DA in behavioral adaptations, in particular for the learning of stimulus-behavior-outcome associations, is beyond doubt now, it is still unclear which mechanisms code for the actual subjective feeling of euphoria. Chronic over-instrumentalization of euphoria-inducing drugs may result in tolerance to the euphoria effects and in an escalation of intake. Acute withdrawal effects are characterized by dysphoria and a depression-like mental state. In nonaddicted users, this can also facilitate drug use in order to overcome the aversive withdrawal states. Entering the “vicious circle” of an escalating consumption and withdrawal is considered to be a gateway to addiction (Heilig & Koob Reference Heilig and Koob2007; Koob & Le Moal Reference Koob and Le Moal2008).

4.2.8. Improved physical appearance and attractiveness

Modern societies impose idealized concepts on males and females, respectively, which include expectations for cognitive and social performance, but also “ideal” norms for physical appearance. Given the natural variation among humans and therefore variance around idealized norms, people feel the pressure to perform behaviors that adapt their physical appearance to these norms. There are certain effects of psychoactive drugs that can be used to facilitate these behaviors and enhance their outcome. A currently predominant case in Western societies may be the pressure toward a lean appearance in females and toward a well-defined muscular appearance in males.

A popular belief is that smoking tobacco reduces body weight. Data indicate that smokers weigh less than non-smokers. However, smokers do not eat less or consume fewer calories than nonsmokers. Several lines of evidence suggest that nicotine causes a less efficient storage of calories, most likely by its interaction with the gut (Wack & Rodin Reference Wack and Rodin1982). Nicotine can also reduce the weight gain usually following smoking cessation (Perkins Reference Perkins1992). It was shown that the activation of nicotinic ACh-receptors in the lateral hypothalamus is the most likely central mechanism by which nicotine interacts with hunger and feeding behavior toward specific food (Jo et al. Reference Jo, Talmage and Role2002).

The use of cocaine and amphetamine and its derivatives for their hunger-suppressing effects has been reported as well (Boys & Marsden Reference Boys and Marsden2003; Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Reference Boys, Marsden and Strang2001; Garattini et al. Reference Garattini, Borroni, Mennini, Samanin, Garattini and Samanin1978). The anorectic effects of amphetamine-derivatives are believed to be mediated mainly by their noradrenergic, rather than by their serotonergic or dopaminergic, effects. In particular, α1 receptor stimulation in the hypothalamus was claimed to be responsible for the reduction in food intake (Borsini et al. Reference Borsini, Bendotti, Carli, Poggesi and Samanin1979; Samanin & Garattini Reference Samanin and Garattini1993).

In males, a well-defined, muscular appearance is considered an ideal. Naturally, this may signal health and potency of the male to a female and increase chances of mating. Physical appearance may be enhanced by sport, exercise, or body-building. The predominant classes of drugs whose effects can be instrumentalized to facilitate exercise-dependent muscular appearance are androgenic-anabolic steroids such as testosterone or nandrolone. Their use to improve physique is especially popular among teenagers (Goldstein Reference Goldstein1990). Anabolic-androgenic steroids increase muscle growth by a peripheral mechanism (Kochakian Reference Kochakian1990). However, they also have direct psychoactive effects, such as an increase in self-esteem (Wood Reference Wood2004; Reference Wood2008). The self-perception of superior physical appearance may also feed back and increase self-confidence and, hence, affect other behaviors such as social approach or sexual behavior (Wood Reference Wood2004). As such, there may be an indirect mechanism of how psychoactive drugs can be instrumentalized to first change physical appearance and as a secondary effect to change mental state and potentially all subsequent behaviors (Brower Reference Brower2002). The slow-acting effects of anabolic-androgenic steroids on mental states are likely to be mediated by their slow effects on the opiate system. Chronic treatment in animals increased levels of the endogenous opioid, β-endorphin, in the limbic system and changed opiate receptor densities. This may be the base for an altered self- and social perception. The modulatory effects on the 5-HT system may account for altered levels of aggression (Kanayama et al. Reference Kanayama, Brower, Wood, Hudson and Pope2009; Quadros et al. Reference Quadros, Takahashi, Miczek, Müller and Jacobs2010).

Several drugs are used to facilitate or inhibit behavior directed toward a change in physical appearance. Although weight reduction appears to be a predominant strategy in females, an increase in muscular appearance is an important goal in males. Both are served by different drug classes. Weight reduction can be achieved by either nicotinic-receptor stimulation or by NA activation. The facilitation of muscle growth relies on a peripheral mechanism involving androgen receptors. This effect is supported by androgen receptor–induced changes in mental states that can facilitate exercise behavior.

Altogether, the functional analysis of nonaddictive psychoactive drug consumption suggests that psychoactive drugs are consumed for their effects on mental states. Based on their ability to adapt food consumption for non-nutritional purposes, humans are able to learn that mental states can be changed by drugs in order to facilitate other, non–drug related behaviors. Specific “instrumentalization goals” are suggested. Available evidence on the neuropharmacological effects of the used psychoactive drugs can in detail support a focused use of a great number of single drug effects for instrumentalization. We suggest that drug instrumentalization may enhance efficacy of specific fitness-relevant behaviors in modern environments. It is assumed that in order to effectively instrumentalize psychoactive drugs, the establishment of and retrieval from a drug memory is required. How this could be done is discussed in section 5.

5. The psychological mechanisms of drug instrumentalization

5.1. Drug memories

A fundamental assumption of the psychoactive drug instrumentalization concept is a memory for all drug-related issues and a systematic retrieval of these memories. In a discussion of addiction-related behaviors, Nancy Mello introduced the idea of a “memory of addiction” (Mello Reference Mello, Kissin and Begleiter1972). Norman White (Reference White1996), in summarizing later evidence, suggested that the reinforcing effects of addictive drugs may in part be brought about by their interaction with the brain's multiple memory systems. He proposed three general types of memory that are independently influenced by psychoactive drugs. These systems would be involved in conditioned incentive learning, declarative learning, and habit or stimulus-response learning (White Reference White1996). An important role of habit learning for drug addiction was previously recognized in particular for drug self-administration behavior (White Reference White1989; Reference White1996). This view received important support by more recent studies demonstrating not only anatomical preconditions in the brain (Haber et al. Reference Haber, Fudge and McFarland2000; Porrino et al. Reference Porrino, Lyons, Smith, Daunais and Nader2004), but also its functional relevance for a transfer of information between stimulus-outcome learning and stimulus-response learning systems (Belin & Everitt Reference Belin and Everitt2008).

Another classification of “addiction memories” suggested at least three different memory types in relation to drug consumption: a memory of a drug effect, a memory of drug use, and a memory of addiction (Boening Reference Boening2001; Heyne et al. Reference Heyne, May, Goll and Wolffgramm2000). Jim Orford (Reference Orford2001) suggested in his “excessive appetite model of addiction” an essential involvement of Pavlovian and incentive learning mechanisms. A combination of operant reward would together with cue-induced conditioned responses drive drug consumption within a social context (Orford Reference Orford2001). A more recent review distinguished brain structures involved in declarative and procedural memory and discussed how these contribute to addiction-related behaviors. Thereby, drugs are assumed to work as unconditioned reinforcers that support emotional learning, hence, encompassing Pavlovian, as well as instrumental, conditioning (Robbins et al. Reference Robbins, Ersche and Everitt2008). Overall, these concepts of drug- or addiction memory have in common the explicit focus on drug addiction, ignoring the fact that in order to establish addiction, a preceding period of nonaddicted drug use must occur. During this period, most (if not all) of the drug-related memories are established, and retrieval of these memories drives ongoing drug consumption.

Some have suggested that drug addiction is based on the vulnerabilities of natural memory systems identified for non-drug-related information (Niaura et al. Reference Niaura, Goldstein and Abrams1991; Redish et al. Reference Redish, Jensen and Johnson2008). We suggest here that nonaddictive psychoactive drug instrumentalization also involves a decision-making process that relies on an interaction of all drug-related memory systems. Parallel to non-drug-related memory systems (Milner et al. Reference Milner, Squire and Kandel1998; Squire et al. Reference Squire, Knowlton and Musen1993), two major drug-memory categories are distinguished: a declarative drug memory and a nondeclarative drug memory (see Fig. 1).

Figure 1. Drug memory systems based on normal memories that psychoactive drugs are likely to influence. A time line suggests the temporal order in which different types of drug memories are established. Drug instrumentalization relies mostly on episodic, semantic, and instrumentally conditioned drug memories. Escalating and compulsory drug use may further intensify these memories. Drug addiction is, in addition, characterized by a growing influence of drug habit and drug priming memories, as well as by classically conditioned drug memories.

The declarative drug memory contains information that is consciously accessible and can be reported verbally in humans. The declarative drug memory should comprise a semantic memory for drug facts and a memory for drug episodes. The semantic memory for a drug contains all impersonal facts, rules, and concepts involving drugs – for example, their names, where they come from, recommended doses, what others report about its effects, and the social rules of their consumption. The establishment of this type of drug memory usually starts before a person is engaged in the first episode of consumption by learning from others about the drug (Leigh & Stacy Reference Leigh and Stacy2004; Miller et al. Reference Miller, Smith and Goldman1990; West Reference West2006). An early semantic drug memory thus shapes the first expectations of drug effects, which is then constantly adapted after actual consumption started (Kidorf et al. Reference Kidorf, Sherman, Johnson and Bigelow1995). It has been suggested that the expectation of drug effects (Del Boca et al. Reference Del Boca, Darkes, Goldman and Smith2002; Leigh Reference Leigh1989) should be conceptualized as a retrieval process from different types of memories (Goldman et al. Reference Goldman, Brown, Christiansen and Smith1991). The expectation of drug effects have been shown to dramatically shape the physiological effects of the drug, as well as its subjective perception (Volkow et al. Reference Volkow, Wang, Ma, Fowler, Zhu, Maynard, Telang, Vaska, Ding, Wong and Swanson2003; Reference Volkow, Wang, Ma, Fowler, Wong, Jayne, Telang and Swanson2006) and, hence, influence the establishment of the episodic drug memory. We hypothesize that a person starts to establish a semantic drug memory as a precondition of psychotropic drug instrumentalization by learning from, for example, media or peer groups, long before the first encounter with the drug.

The episodic drug memory comprises the memories of personally experienced episodes with the drug. It is an autobiographical memory on the “what,” “where,” and “when” of the personal drug encounters (Dere et al. Reference Dere, Easton, Nadel and Huston2008). This may include memories of subjectively experienced acute drug effects – for example, the mental states the drug induced. The episodic drug memory system can also contain memories of what was done during a particular drug-induced mental state and even what effects it had in terms of the environmental feedback (Boening Reference Boening2001).

Although the experience of euphoria is often the sought-after mental state, it is not the only one on the timescale of a drug episode. A single drug episode may better be considered as a sequence of several distinct mental states. Experimental studies in animals and humans have shown that it takes a few experiences of the drug effects to reliably distinguish them from placebo. Once established, however, they can be retrieved from memory and provide the base for other behavioral choices (Overton Reference Overton1968; Stolerman Reference Stolerman1992). As such, this type of memory appears to be crucial for establishing drug instrumentalization (Eissenberg & Balster Reference Eissenberg and Balster2000; Miller Reference Miller2001).

The nondeclarative drug memory, in contrast, is not consciously accessible and can be inferred only from behavioral changes. The nondeclarative drug memories contain engrams of the classically conditioned drug memory, instrumentally conditioned drug memory, habit memory, procedural drug memories, and drug-priming memories (see also Orford Reference Orford2001; Robbins et al. Reference Robbins, Ersche and Everitt2008).

Classically conditioned drug memories may contain all drug effects that refer to the process of Pavlovian conditioning (Bouton & Moody Reference Bouton and Moody2004). These may include, for example, the sensitization of the acute drug effects (Kalivas et al. Reference Kalivas, Sorg and Hooks1993; Vanderschuren & Kalivas Reference Vanderschuren and Kalivas2000), drug tolerance, conditioned locomotor activity, conditioned emotional and physiological responses (Foltin & Haney Reference Foltin and Haney2000), and conditioned withdrawal effects (Goldberg Reference Goldberg1975; O'Brien et al. Reference O'Brien, Childress, Ehrman and Robbins1998; Siegel Reference Siegel1988).

Instrumentally conditioned drug memories comprise engrams established by instrumental conditioning. Major behaviors induced by these engrams are drug seeking and drug self-administration (Richardson & Roberts Reference Richardson and Roberts1996; Spealman & Goldberg Reference Spealman and Goldberg1978). These memories also include drug cues that can serve as secondary reinforcers, as shown in conditioned place preference (Bardo & Bevins Reference Bardo and Bevins2000; Childs & de Wit Reference Childs and de Wit2009; Tzschentke Reference Tzschentke2007), or which can reinstate drug seeking and drug self-administration (de Wit & Stewart Reference de Wit and Stewart1981; Shaham et al. Reference Shaham, Shalev, Lu, de Wit and Stewart2003; Wikler Reference Wikler1973). They may also include memories established by social learning, for example, by observation (Bandura Reference Bandura1977). A motivation to use a drug may induce a cognitive process dealing with the outcome expectancies of the drug consumption (Marlatt & George Reference Marlatt and George1984). Behaviors started by this process may then be positively or negatively reinforced by the drug effects (Koob & Le Moal Reference Koob and Le Moal1997; West Reference West2006).

Drug habit memories refer to instrumental behavior that is no longer goal-directed but stimulus-controlled –a behavioral response that is triggered by a cue – but independent from its behavioral consequences (Robbins & Everitt Reference Robbins and Everitt1996). This type of memory plays an important role in the transition from controlled to compulsive drug use and addiction (Belin & Everitt Reference Belin and Everitt2008; Porrino et al. Reference Porrino, Lyons, Smith, Daunais and Nader2004) but may already play a big role in stimulus-driven drug instrumentalization in non-addicted drug users.

Procedural drug memories comprise all memories for skills involved in handling a drug. This may range from its production (e.g., cooking up heroin; building a joint) to the actual method of self-administration (e.g., snorting cocaine; setting a needle for an IV heroin injection).

Drug priming memories refer to those engrams whose activation by a small amount of the drug, which would not induce major subjective and behavioral effects in drug naïve individuals, may in an experienced user induce drug-related behavior (e.g., reinstate drug seeking, conditioned place preference, or self-administration) and subjective effects.

5.2. A two-stage model of drug instrumentalization learning

Based on interplay of different types of drug memories, we propose a two-stage model for drug instrumentalization learning. Because the crucial function of psychoactive drug-instrumentalization is to enhance efficacy of previously learned behaviors, a precondition for this model is an already established behavior that is reflected at the level of the brain, for example in stimulus-response or stimulus-action-outcome associations. In a drug-free state (Fig. 2A) a stimulus (S x ) activates in a particular environmental context, a particular action and an action-outcome representation in the brain. Both facilitate a behavioral response (R x ). The behavior R x yields an action outcome, which is perceived and processed. A comparator function weighs the expected outcome against the actually perceived outcome. The difference in expectation of outcome (ΔEo) serves as a teaching signal to strengthen or weaken the associations of the S x with an action representation and with an action outcome expectation. In constant environments with well-established S-R and stimulus-action-outcome associations, ΔEo will approach zero, indicating an optimal adjustment of action expectation to action outcome. For reasons of simplicity, it will at this stage not be differentiated between approach and consummatory behavior (Ikemoto & Panksepp Reference Ikemoto and Panksepp1999; Robinson & Berridge Reference Robinson and Berridge1993). Both could be considered in this model in a sequential order of approach and consumption.

Figure 2. A two-stage model of drug instrumentalization based on the interplay of different drug memories. Drug instrumentalization is based on previously learned instrumental behavior reflected at the level of the brain in stimulus-response and stimulus-action-outcome associations.

During drug instrumentalization – learning (Fig. 2B), the organism learns how to change its mental state in a way that allows a more effective performance of an already established behavior. In Stage I, a specific stimulus (Sy) triggers a psychoactive drug-taking response (R y ). S y summarizes a number of possible and well-described scenarios that lead to initial drug taking, such as peer group pressure, as well as the information on the drug itself as part of the semantic drug memory. The consequence (action outcome) of Ry is an altered mental state of the organism (ΔMs), which is perceived by the organism. It depends in its nature on the pharmacological properties of the drug. The learning of the S y -R y -ΔMs association requires procedural-, instrumental conditioned-, as well as episodic drug memories. Although R y may initially be under control of the action outcome (ΔMs) and semantic memories, this control can shift with excessive repetition. R y then becomes S y -controlled, which involves drug habit memories. During Stage II, the already established instrumental response based on the S x -R x association is performed, but under the new mental state (ΔMs). If ΔMs proves to facilitate the ability of S x to activate the associated action-representation or the way in which the action-representation induces behavioral activity, the R x will be performed more efficiently. Hence, the action outcome is enhanced when the R x is performed under ΔMs. The comparator detects a positive difference between the action-outcome expectation, which was generated during a nondrugged mental state, and the actual outcome achieved under ΔMs. This difference (ΔEo) serves as a teaching signal that not only reinforces the association of S x with an action representation and its action-outcome expectation in Stage II, but also strengthens the association of S y with R y and its outcome ΔMs.

During drug instrumentalization – retrieval (Fig. 2C), an organism is using the learned information of how a self-generated, “on purpose” mental state change can facilitate a subsequent behavior and maximize its outcome. For that to occur, the presence of both stimuli, S y and S x , is required. In Stage I, S y triggers R y , which leads to ΔMs with the expectation to perform the instrumental response R x more efficiently. Once ΔMs is achieved, S x can now more efficiently activate the action and action-outcome representations and induce R x . The enhanced performance of R x under ΔMs is generating a better action-outcome than under a drug-free mental state. If environmental circumstances and ΔMs-enhanced action-outcome remain constant (i.e., no tolerance or sensitization develops), there will be no negative teaching signal ΔEo generated, and the associations of S y -R y -ΔMs and S x -R x are maintained.

6. Ontogeny of drug instrumentalization

6.1. Drug instrumentalization establishment during a lifetime

Although one can read about, and establish a factual knowledge on, the effects of drugs, more is learned during experimental consumption when a number of drug memories become established (Maloff et al. Reference Maloff, Becker, Fonaroff, Rodin, Zinberg and Harding1981). This usually starts during late childhood and early adolescence (Sher et al. Reference Sher, Grekin and Williams2005), when undifferentiated consumption develops into a highly specific pattern of consumption (Kuntsche et al. Reference Kuntsche, Knibbe, Gmel and Engels2006; Spear Reference Spear2000). Experimental consumption, in contrast to instrumentalization and compulsive consumption, refers to a consummatory behavior during which the consequences are initially mostly unknown to the individual. Although there are expectancies of the drug effects in drug naïve consumers (Brown Reference Brown1985; Brown et al. Reference Brown, Goldman, Inn and Anderson1980; Gustafson Reference Gustafson1991; Miller et al. Reference Miller, Smith and Goldman1990; Peele & Brodsky Reference Peele and Brodsky2000), the individual response profile after first consumption is virtually unpredictable (e.g., Jones Reference Jones1971; Waskow et al. Reference Waskow, Olsson, Salzman and Katz1970). During experimental consumption, the effects of a drug are explored at usually different doses and settings (Maloff et al. Reference Maloff, Becker, Fonaroff, Rodin, Zinberg and Harding1981; Patrick & Maggs Reference Patrick and Maggs2008). At the same time, there is also experimentation with how the drug's effects on mental states can be “used” in relation to different settings (Harding & Zinberg Reference Harding, Zinberg and Du Toit1977; Simons et al. Reference Simons, Correia and Carey2000; Zinberg Reference Zinberg1984). The perceived usefulness was found to predict future use of the drug (Boys & Marsden Reference Boys and Marsden2003; Boys et al. Reference Boys, Marsden, Griffiths, Fountain, Stillwell and Strang1999; Leigh & Stacy Reference Leigh and Stacy2004).

The introduction to the drug, appropriate settings, and possible instrumentalizations are usually performed by older and more experienced members of the peer group (e.g., Eissenberg & Balster Reference Eissenberg and Balster2000; Friedman et al. Reference Friedman, Lichtenstein and Biglan1985). However, given interindividual differences in drug pharmacokinetics and -dynamics, in personality, and in life circumstances, each person customizes his or her drug use. In fact, the individual learns about which mental states the drug can induce at different doses and how this new mental state can be used, as well as how to control consumption (Bruehl et al. Reference Bruehl, Lende, Schwartz, Sterk and Elifson2006). For an “optimal” drug instrumentalization that yields the greatest benefits, a well-controlled consumption may be established in relation to the following parameters: goals for instrumentalization, appropriate type of drug, appropriate dose of this drug, and setting for consumption. A systematic drug use can thus become an integral part of a person's life within a socially acceptable range of behaviors (Davies Reference Davies1997; Heath Reference Heath2000; Waldorf et al. Reference Waldorf, Reinarman and Murphy1991; Zinberg et al. Reference Zinberg, Harding, Stelmack and Marblestone1978).

6.2. Benefits versus adverse effects of psychoactive drug use

Although we argue for evolutionary benefits of non-addictive drug use here, we also must emphasize that the instrumentalization of psychoactive drugs comes at a price, which ultimately qualifies it as a risky behavior (Donovan & Richard Reference Donovan and Richard1985; Hill & Chow Reference Hill and Chow2002). Severe damage to the brain and body peripheral organs have been documented, for example, from alcohol (Harper Reference Harper2007; Parsons Reference Parsons1998; Ward et al. Reference Ward, Lallemand and de2009), MDMA (Gouzoulis-Mayfrank & Daumann Reference Gouzoulis-Mayfrank and Daumann2009; Seiden & Sabol Reference Seiden and Sabol1996); nicotine (Ray et al. Reference Ray, Schnoll and Lerman2009), androgenic-anabolic steroids (Wood Reference Wood2004), psychostimulants (Pascual-Leone et al. Reference Pascual-Leone, Dhuna and Anderson1991; Volkow et al. Reference Volkow, Hitzemann, Wang, Fowler, Wolf, Dewey and Handlesman1992), and cannabis (Solowij Reference Solowij1998). Many psychoactive drugs enhance preexisting psychopathologies in vulnerable individuals (e.g., Andreasson et al. Reference Andreasson, Allebeck, Engstrom and Rydberg1987; Reference Andreasson, Allebeck and Rydberg1989; Negrete Reference Negrete, Nahas and Latour1993).

We argue here that in the majority of nonaddicted psychoactive drug users, there are beneficial effects on self-maintenance or reproduction rate – or both – from drug use in the way that established instrumentalization may in particular at a younger age outweigh the drug-induced decline in health later in life (Crawford Reference Crawford2000; Lende Reference Lende, Wenda Trevathan, Smith and McKenna2007; Peele & Brodsky Reference Peele and Brodsky2000). As such, the behavior of psychotropic drug instrumentalization may have a heritable component (Schumann Reference Schumann2007) that is maintained in an antagonistic pleiotropy (Williams Reference Williams1957). This view is supported by life history research, which shows that risky alcohol consumption peaks at an age of 18–19 (males) and 16–17 (females) and declines thereafter (Hill & Chow Reference Hill and Chow2002; Jessor Reference Jessor1987; Johnstone et al. Reference Johnstone, Leino, Ager, Ferrer and Fillmore1996). The peak occurs at a stage of high reproductive efforts. In particular, mating efforts (locating mate, courtship) are high (Chisholm Reference Chisholm1993). Prior to marriage and continuing thereafter, risky alcohol consumption goes down (Leonard & Das Eiden Reference Leonard and Das Eiden1999; Miller-Tutzauer et al. Reference Miller-Tutzauer, Leonard and Windle1991) and many pregnant women give up drinking (Nilsen et al. Reference Nilsen, Holmqvist, Hultgren, Bendtsen and Cedergren2008). At that stage, parenting efforts usually increase (Chisholm Reference Chisholm1993), which are not supported but rather diminished by psychoactive drug effects. We suggest that because individual resource allocations change during life history, so do instrumentalization goals and, ultimately, non-addictive psychoactive drug consumption (Heyman Reference Heyman1996; Hill & Chow Reference Hill and Chow2002).

The major downside of drug instrumentalization, which as yet has prevented the scientific community from acknowledging any adaptational function or effect of drug taking behavior, is the risk of developing drug addiction (Nutt et al. Reference Nutt, King, Saulsbury and Blakemore2007). People who use and instrumentalize drugs are at a higher risk to develop drug addiction as a psychiatric disorder (American Psychiatric Association 1994) than are drug abstainers (Kendler et al. Reference Kendler, Prescott, Myers and Neale2003a). A striking feature of the definition of addiction is the compulsive seeking and consumption of the drug, which is no longer a controlled, goal-directed instrumentalization. Drug addiction is usually associated with an escalating consumption of large amounts of the drug. This significantly increases the impact of any toxic drug effects and directly leads every year to drug-related fatalities (e.g., EMCDDA 2009).

In this case, the adverse drug effects by far outweigh the possible use of any instrumentalization. Natural goals are devalued in the course of addiction development (Redish et al. Reference Redish, Jensen and Johnson2008). It is highly unlikely that this form of drug consumption might have any adaptational function at all. It has been argued that even drug addiction may be an adaptation to cope with “integration failure” (Alexander Reference Alexander1987; Reference Alexander1990). This view highlights the important role of adaptation problems at the personal level for the continuation of psychoactive drug consumption. The first steps of later-stage addicts are indeed to establish non-addictive drug consumption during which they usually instrumentalize the drug effects in the above-described way. Eventually, the capacity of a drug for instrumentalization is exceeded, and no further improvement of non–drug related behavior can be achieved. Then, psychoactive drug use may not help to solve an individual adaptation problem, but, by its toxic side effects, impairs the organism. Altogether, the instrumentalization of psychotropic drugs may have adaptational effects only in non-addicts, being no longer beneficial when the individual loses control and develops drug addiction.

7. Possible implications for drug policy

Epidemiological, ethological, social, psychological, genetic, and psychiatric data on drug addiction are shaping a number of scientific theories, which often have a different focus (West Reference West2006). A major criterion for the quality of a theory is not only how well it integrates empirical evidence and gray literature into a logical framework, but also the quality of its predictions. In terms of theories about drug use and addiction, these criteria might be rephrased as: (1) how well does the framework explain psychoactive drug use in drug addicts and in non-addicts, and (2) how effective are the predictions derived from the framework to avoid adverse effects of drug taking behavior, such as addiction, and treat these effects once they occur. The first criterion is targeted by the presented framework from an evolutionary perspective, suggesting an adaptive function of non-addictive drug use, but stressing reduced chances of survival and reproduction in drug addiction. What can be derived to serve the second criterion when dealing with drug instrumentalization? The proposed concept of non-addictive drug instrumentalization might refine the way in which to deal with psychoactive drugs. As an extension to previous prevention programs that were limited in their success (Brown & Kreft Reference Brown and Kreft1998), these approaches might be tailored to the different stages of the potential and actual drug user's development and a “successful” drug instrumentalization:

  1. A. For drug-naïve individuals, who are usually in the adolescent to early adult age, information should be systematically provided not only on the adverse effects of addiction and accidental overdosing, but also on how drugs are instrumentalized. Although this might not prevent the initial experimentation with available drugs, it might change attitudes when it comes to the establishment of regular intake patterns. The goal should not be to prevent drug use in general, but to foster control over it by the individual from early stages of use with a better awareness of the full range of the behavioral mechanisms involved.

  2. B. For people who have already integrated drugs in their routines, it is important to emphasize the need to stay in control of drug use. In particular, during periods of transition in life when new demands occur, there is an increased danger of developing new forms of drug instrumentalization. One of these periods is adolescence (NatCent/NFER 2006). Humans appear to be especially sensitive to drug effects during adolescence (Spear Reference Spear2000). In this phase of life, many new demands occur that are prone to drug instrumentalization, such as sexual maturation, peer group pressure, socialization with the opposite sex, and increased cognitive demands at school and work. This is also the first time in life when several drugs become accessible and experimental consumption starts. But this is not the only transition period with an increase in demands. Later in life, when, for example, professional development settles at a high level and performance needs to be maintained at that level, stress load almost certainly increases. Periods of transition should be a major focus when prevention strategies for drug instrumentalization are considered. We argue that psychotropic drug use can have beneficial effects for an individual in modern environments. Nevertheless, one should attempt to limit the extent to which psychotropic drugs are instrumentalized. This can be done by a systematic analysis of the personal instrumentalization pattern, asking, for example, which drugs are instrumentalized, how often, and for which goals. Possibly, educational programs should aim to train young people to self-analyze their drug instrumentalization and seek help when coming to the conclusion that certain goals in life cannot be achieved without extensive psychotropic drug use.

    The occurrence of drug instrumentalization can be seen as an indicator that particular goals are not (or are less easily) achieved by “natural means.” Once these goals are identified, particular training may be sought to focus on them and to reduce the extent the drug is used for each goal. Analysis and training could be provided at a personal level or, if an instrumentalization pattern prevails in a particular group, also at family, school, or community levels. People might be trained from early age to learn how to control mental states without pharmacological means (i.e., by own mental resource management, stress-recovery management, relaxation training, controlled disinhibition and approach in social settings).

  3. C. For people who have integrated regular drug use in their life's routines and who are at risk of a transition to drug addiction, over-instrumentalization of drugs and, hence, a dependence on the drug to achieve major goals in life, needs to be prevented. Also at this stage, a careful analysis of personal instrumentalization patterns and how they developed over time is required. An initial control for that should be part of a medical routine screen with the intention of preventing over-instrumentalization at an early age. It might be a useful refinement in medical interviews not only to ask for the amount of a drug consumed, but also to identify instrumentalization patterns and the degree the drug is required for achieving major personal goals in life. A more careful investigation might also include a drug-instrumentalization biography and a detailed assessment of the types and intensity of drug memories already established (Orford Reference Orford2008; Redish et al. Reference Redish, Jensen and Johnson2008).

    Based on that, alternative ways to achieve these goals may need to be identified and intensely trained. With the advent of a more individualized addiction treatment strategy (Conrod et al. Reference Conrod, Pihl, Stewart and Dongier2000; Reference Conrod, Stewart, Comeau and Maclean2006), factors like personality traits and genetic predictors may be useful identifying individuals who are prone to having problems achieving critical goals in life and who might be at greater risk of losing control over drug instrumentalization (Goldman et al. Reference Goldman, Oroszi and Ducci2005; Kreek et al. Reference Kreek, Nielsen, Butelman and Laforge2005; Spanagel et al. Reference Spanagel, Pendyala, Abarca, Zghoul, Sanchis-Segura, Magnone, Lascorz, Depner, Holzberg, Soyka, Schreiber, Matsuda, Lathrop, Schumann and Albrecht2005; Woicik et al. Reference Woicik, Stewart, Pihl and Conrod2009). However, environmental factors and their interactions with genetic factors might also serve as biomarkers for an increased risk of drug instrumentalization and over-instrumentalization (Blomeyer et al. Reference Blomeyer, Treutlein, Esser, Schmidt, Schumann and Laucht2008; Kendler et al. Reference Kendler, Jacobson, Prescott and Neale2003b; Sher et al. Reference Sher, Grekin and Williams2005).

8. Testing drug instrumentalization empirically

Whether drug instrumentalization can serve as a framework to explain large-scale, non-addictive psychoactive drug consumption in animals and humans needs to be tested empirically. Assumptions, as well as predictions, would require testing. At the level of the assumptions, testing the different types of drug memories and their establishment in the life-course is suggested. This may be done by modifying respective paradigms from non-drug memory assessment. To test predictions in humans, it would be crucial to identify instrumentalization profiles for individual drug users and evaluate the extent of drug-specific instrumentalization in the population of users. Because the full extent of the mechanisms of drug instrumentalization (e.g., non-declarative memory-based behaviors) is not consciously accessible to the user, simple self-reports may not be sufficient. Structured interviews or specifically designed questionnaires, which probe for the individual's relationship with the drugs consumed, with all potential instrumentalization goals, may be more adequate.

At the mechanistic level, animal models of drug instrumentalization may be useful for testing the origin of the behavior and its neurophysiological prerequisites. In contrast to present animal models of drug self-administration (Olmstead Reference Olmstead2006; Sanchis-Segura & Spanagel Reference Sanchis-Segura and Spanagel2006), animals should be given the chance to instrumentalize the drug self-administration behavior to enhance their performance in non–drug related behaviors. It may also be interesting to investigate in ethological studies of drug consumption in animals, whether related behaviors can be identified whose performance is enhanced in a functional way by the pharmacological effects of the psychotropic drug (e.g., Wiens et al. Reference Wiens, Zitzmann, Lachance, Yegles, Pragst, Wurst, von Holst, Guan and Spanagel2008).

9. Summary

Non-addictive psychoactive drug use appears to be much more common than drug addiction in humans around the globe. Although drug addiction as a psychiatric disease results in severe adverse effects on individuals and societies, non-addictive drug use is chosen for its positive effects. We have argued that non-addictive drug use may have a number of beneficial effects on behaviors relevant for survival and reproduction, which may explain the persistence of drug use in human societies. The basic mechanisms establishing non-addictive psychoactive drug use may have arisen in ancient environments, coming to full expression under more recent environmental changes. The key psychological argument is that drugs are used because their psychoactive effects can be instrumentalized. Drug instrumentalization is defined here as a learned behavior to change one's own mental state by consuming a psychoactive drug. Subsequently, this altered mental state allows the more effective pursuit of central survival- and reproduction-relevant goals. A better understanding of the mechanisms of psychotropic drug use in non-addicts might serve to better prevent the transition to drug addiction in the future.

Toward an evolutionary basis for resilience to drug addiction Ahmed, Serge H. Université Bordeaux Ségalen, Institut des Maladies Neurodégénératives, UMR CNRS 5293, 33076 Bordeaux, France. http://imn-bordeaux.org Drugs' rapid payoffs distort evaluation of their instrumental uses Ainslie, George Department of Commerce, University of Cape Town, Rondebosch 7701, South Africa; 151 Veterans Affairs Medical Center, Coatesville, PA 19320. picoeconomics.org Drugs as instruments from a developmental child and adolescent psychiatric perspective Banaschewski, Tobias, Blomeyer, Dorothea, Buchmann, Arlette F., Poustka, Luise, Rothenberger, Aribert and Laucht, Manfred Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, 68159 Mannheim, Germany. www.zi-mannheim.de; Department of Child and Adolescent Psychiatry and Psychotherapy, University of Göttingen, 37075 Göttingen, Germany. Drug use as consumer behavior Foxall, Gordon Robert and Sigurdsson, Valdimar Cardiff Business School, Aberconway Building, Colum Drive, Cardiff, CF10 3EU, United Kingdom. http://www.cardiff.ac.uk/carbs/faculty/foxall/index.html; School of Business, Reykjavik University, Menntavegur 1, Nauthólsvík, 101 Reykjavík, Iceland. http://www.ru.is/starfsfolk/valdimars Nonaddictive instrumental drug use: Theoretical strengths and weaknesses Goudie, Andrew J., Gullo, Matthew J., Rose, Abigail K., Christiansen, Paul, Cole, Jonathan C., Field, Matt and Sumnall, Harry Experimental Psychology, Liverpool University, Liverpool L69 7ZA, United Kingdom. http://www.liv.ac.uk/psychology/staff/agoudie.html; Faculty of Health and Applied Social Sciences, Liverpool John Moores University, Liverpool L3 2AY, United Kingdom. Non-addictive psychoactive drug use: Implications for behavioral addiction Griffiths, Mark D. International Gaming Research Unit, Psychology Division, Nottingham Trent University, Nottingham NG1 4BU, United Kingdom. http://www.ntu.ac.uk/apps/Profiles/51652-1-4/Professor_Mark_Griffiths.aspx Does drug mis-instrumentalization lead to drug abuse? Kippin, Tod E. Department of Psychological and Brain Sciences & the Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106-9660. http://www.psych.ucsb.edu/ Drug instrumentalization and evolution: Going even further Lende, Daniel H. Department of Anthropology, University of South Florida, Tampa, FL 33620. http://blogs.plos.org/neuroanthropology/ Optimal drug use and rational drug policy Miller, Geoffrey F. Psychology Department, University of New Mexico, Albuquerque, NM 87131-1161. http://www.unm.edu/~psych/faculty/lg_gmiller.html Sacramental and spiritual use of hallucinogenic drugs Móró, Levente and Noreika, Valdas Centre for Cognitive Neuroscience, Department of Psychology, University of Turku, FI-20014 Turku, Finland. http://users.utu.fi/~leve; Oxford Centre for Human Brain Activity, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, United Kingdom. http://www.psy.utu.fi/henkilot/valdasnoreika.htm The instrumental rationality of addiction Pickard, Hanna Oxford Centre for Neuroethics, Department of Philosophy, University of Oxford, Oxford OX1 1PT; All Souls College, Oxford OX1 4AL; Complex Needs Service, Oxford Health NHS Trust, Oxford OX4 1XE, United Kingdom. http://www.philosophy.ox.ac.uk/members/hanna_pickard Drug addiction finds its own niche Reid, Alastair Oxford Health NHS Foundation Trust, Specialist Community Addiction Service, The Valley Centre, High Wycombe, Bucks HP13 6EQ, United Kingdom. Why do we take drugs? From the drug-reinforcement theory to a novel concept of drug instrumentalization Spanagel, Rainer Institute of Psychopharmacology, Central Institute of Mental Health (CIMH), University of Heidelberg, 68159 Mannheim, Germany. www.zi-mannheim.de But is it evolution…? Sullivan, Roger J. and Hagen, Edward H. Department of Anthropology, CSU Sacramento, Sacramento CA 95816. http://www.csus.edu/indiv/s/sullivanr/; Department of Anthropology, Washington State University, Vancouver, WA 98686-9600. http://anthro.vancouver.wsu.edu/faculty/hagen Flaws of drug instrumentalization Swendsen, Joel and Le Moal, Michel Université de Bordeaux, National Center for Scientific Research (CNRS 5287), 33000 Bordeaux cedex – France. ; INSERM, U862, Neurocentre Magendie, Neurogenesis and pathophysiology, Bordeaux F-33000, France. ; Université de Bordeaux, Bordeaux F-33000, France. Psychoactive drug use: Expand the scope of outcome assessment Troisi, Alfonso Department of Neuroscience, University of Rome Tor Vergata, 00133 Rome, Italy. http://web.uniroma2.it/medicinait.php Drugs, mental instruments, and self-control Van Gulick, Robert Department of Philosophy, Syracuse University, Syracuse, NY 13244. http://philosophy.syr.edu/ Aspects of nicotine utilization Warburton, David M. Reading University, Psychology, Reading University, Reading RG6 6AL, United Kingdom. Governing drug use through neurobiological subject construction: The sad loss of the sociocultural Wu, Kevin Chien-Chang National Taiwan University College of Medicine, Taipei 100, Taiwan. http://www.ntu.edu.tw/ To use or not to use: Expanding the view on non-addictive psychoactive drug consumption and its implications Müller, Christian P. and Schumann, Gunter Section of Addiction Medicine, Department of Psychiatry and Psychotherapy, University of Erlangen–Nuremberg, 91054 Erlangen, Germany. http://www.psychiatrie.uk-erlangen.de/wir_ueber_uns/mitarbeiter/e3000/index_ger.html; MRC SGDP-Center, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, United Kingdom. http://www.iop.kcl.ac.uk/staff/profile/default.aspx?go=10977

ACKNOWLEDGMENTS

We thank Dr. Cathy Fernandes, Miss Alanna Easton, and the anonymous reviewers for their constructive comments on the manuscript. We also acknowledge the helpful editorial advice from Dr. Barbara Finlay. This work was supported by the UK Department of Health NIHR Biomedical Centre for Mental Health and the MRC-SGDP Centre at the Institute of Psychiatry, King's College London (UK) and funds of the University of Erlangen-Nuremberg (Germany).

References

Adell, A., Bortolozzi, A., Diaz-Mataix, L., Santana, N., Celada, P. & Artigas, F. (2010) Serotonin interaction with other neurotransmitter systems. In: Handbook of the behavioral neurobiology of serotonin, ed. Müller, C. P. & Jacobs, B. L., pp. 259–76. Academic Press.CrossRefGoogle Scholar
Aghajanian, G. K. & Marek, G. J. (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36:589–99.CrossRefGoogle ScholarPubMed
Alexander, B. K. (1987) The disease and adaptive models of addiction: A framework analysis. Journal of Drug Issues 17:4766.Google Scholar
Alexander, B. K. (1990) The empirical and theoretical bases for an adaptive model of addiction. Journal of Drug Issues 20:2937.CrossRefGoogle Scholar
Allison, C. & Pratt, J. A. (2003) Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacology and Therapeutics 98:171–95.Google Scholar
Alvergne, A., Jokela, M. & Lummaa, V. (2010) Personality and reproductive success in a high-fertility human population. Proceedings of the National Academy of Sciences USA 107(26):11745–50.CrossRefGoogle Scholar
Amendt, G. (2003) No drugs no future. Europa Verlag.Google Scholar
Ameri, A. (1999) The effects of cannabinoids on the brain. Progress in Neurobiology 58:315–48.CrossRefGoogle ScholarPubMed
American Psychiatric Association (1994) Diagnostic statistical manual of mental disorders, 4th ed. (DSM-IV). American Psychiatric Press Inc.Google Scholar
Anders, G. (1956) Die Antiquiertheit des Menschen, Band 1: Über die Seele im Zeitalter der zweiten industriellen Revolution [The obsolescence of human beings, volume 1: The soul in the age of the second industrial revolution]. C. H. Beck.Google Scholar
Anderson, P. & Baumberg, B. (2006) Alcohol in Europe. Institute of Alcohol Studies.Google Scholar
Andreasson, S., Allebeck, P., Engstrom, A. & Rydberg, U. (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2(8574):1483–86.CrossRefGoogle ScholarPubMed
Andreasson, S., Allebeck, P. & Rydberg, U. (1989) Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatrica Scandinavia 79(5):505–10.CrossRefGoogle ScholarPubMed
Arria, A. M. & Wish, E. D. (2006) Nonmedical use of prescription stimulants among students. Pediatric Annals 35:565–71.CrossRefGoogle ScholarPubMed
Arroyo, M., Markou, A., Robbins, T. W. & Everitt, B. J. (1998) Acquisition, maintenance and reinstatement of intravenous cocaine self-administration under a second-order schedule of reinforcement in rats: Effects of conditioned cues and continuous access to cocaine. Psychopharmacology 140(3):331–44.CrossRefGoogle Scholar
Aston-Jones, G., Rajkowski, J. & Cohen, J. (1999) Role of locus coeruleus in attention and behavioral flexibility. Biological Psychiatry 46:1309–20.CrossRefGoogle ScholarPubMed
Axelrod, R. & Hamilton, W. D. (1981) The evolution of cooperation. Science 211(4489):1390–96.CrossRefGoogle ScholarPubMed
Bandura, A. (1977) Self-efficacy: Toward a unifying theory of behavioral change. Psychological Review 84(2):191215.Google Scholar
Bardo, M. T. (1998) Neuropharmacological mechanisms of drug reward: Beyond dopamine in the nucleus accumbens. Critical Reviews in Neurobiology 12:3767.CrossRefGoogle ScholarPubMed
Bardo, M. T. & Bevins, R. A. (2000) Conditioned place preference: What does it add to our preclinical understanding of drug reward? Psychopharmacology (Berlin) 153(1):3143.CrossRefGoogle ScholarPubMed
Baum-Baicker, C. (1985) The psychological benefits of moderate alcohol consumption: A review of the literature. Drug and Alcohol Dependence 15:305–22.CrossRefGoogle ScholarPubMed
Belin, D. & Everitt, B. J. (2008) Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 57(3):432–41.CrossRefGoogle ScholarPubMed
Berridge, K. C. (1996) Food reward: Brain substrates of wanting and liking. Neuroscience and Biobehavioral Reviews 20:125.CrossRefGoogle ScholarPubMed
Berridge, K. C. & Robinson, T. E. (2003) Parsing reward. Trends in Neurosciences 26:507–13.CrossRefGoogle ScholarPubMed
Bierut, L. J., Dinwiddie, S. H., Begleiter, H., Crowe, R. R., Hesselbrock, V., Nurnberger, J. I. Jr., Porjesz, B., Schuckit, M. A. & Reich, T. (1998) Familial transmission of substance dependence: Alcohol, marihuana, cocaine, and habitual smoking: A report from the Collaborative Study on the Genetics of Alcoholism. Archives of General Psychiatry 55:982–88.CrossRefGoogle Scholar
Blokland, A. (1995) Acetylcholine: A neurotransmitter for learning and memory? Brain Research Reviews 21:285300.CrossRefGoogle ScholarPubMed
Blomeyer, D., Treutlein, J., Esser, G., Schmidt, M. H., Schumann, G. & Laucht, M. (2008) Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biological Psychiatry 63(2):146–51.CrossRefGoogle ScholarPubMed
Boening, J. A. (2001) Neurobiology of an addiction memory. Journal of Neural Transmission 108 (6):755–65.Google Scholar
Bonn-Miller, M. O., Zvolensky, M. J. & Bernstein, A. (2007) Marihuana use motives: Concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marihuana smokers. Addictive Behavior 32:4962.CrossRefGoogle Scholar
Booth, C. & Hasking, P. (2009) Social anxiety and alcohol consumption: The role of alcohol expectancies and reward sensitivity. Addictive Behaviors 34(9):730–36.CrossRefGoogle ScholarPubMed
Borsini, F., Bendotti, C., Carli, M., Poggesi, E. & Samanin, R. (1979) The roles of brain noradrenaline and dopamine in the anorectic activity of diethylpropion in rats: A comparison with d-amphetamine. Research Communications in Chemical Pathology and Pharmacology 26:311.Google ScholarPubMed
Bouton, M. E. & Moody, E. W. (2004) Memory processes in classical conditioning. Neuroscience & Biobehavioral Reviews 28(7):663–74.Google Scholar
Boyd, C. J., McCabe, S. E., Cranford, J. A. & Young, A. (2006) Adolescents' motivations to abuse prescription medications. Pediatrics 118(6):2472–80.Google Scholar
Boyd, C. J., Teter, C. J., West, B. T., Morales, M. & McCabe, S. E. (2009) Non-medical use of prescription analgesics: A three-year national longitudinal study. Journal of Addictive Diseases 28:232–42.Google Scholar
Boys, A. & Marsden, J. (2003) Perceived functions predict intensity of use and problems in young polysubstance users. Addiction 98(7):951–63.CrossRefGoogle ScholarPubMed
Boys, A., Marsden, J., Griffiths, P., Fountain, J., Stillwell, G. & Strang, J. (1999) Substance use among young people: The relationship between perceived functions and intentions. Addiction 94(7):1043–50.CrossRefGoogle ScholarPubMed
Boys, A., Marsden, J. & Strang, J. (2001) Understanding reasons for drug use amongst young people: A functional perspective. Health Education Research 16:457–69.CrossRefGoogle ScholarPubMed
Bradizza, C. M., Reifman, A. & Barnes, G. M. (1999) Social and coping reasons for drinking: Predicting alcohol misuse in adolescents. Journal of Studies on Alcohol 60:491–99.CrossRefGoogle ScholarPubMed
Brischoux, F., Chakraborty, S., Brierley, D. I. & Ungless, M. A. (2009) Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. Proceedings of the National Academy of Sciences USA 106:4894–99.CrossRefGoogle ScholarPubMed
Britt, G. C. & McCance-Katz, E. F. (2005) A brief overview of the clinical pharmacology of “club drugs.” Substance Use and Misuse 40:1189–201.CrossRefGoogle ScholarPubMed
Bronfenbrenner, U. (1994) Ecological models of human development. In: International encyclopedia of education, pp. 1643–47. Elsevier Sciences.Google Scholar
Brower, K. J. (2002) Anabolic steroid abuse and dependence. Current Psychiatry Reports 4:377–87.CrossRefGoogle ScholarPubMed
Brown, J. H. & Kreft, I. G. (1998) Zero effects of drug prevention programs: Issues and solutions. Evaluation Review 22:314.CrossRefGoogle Scholar
Brown, S. A. (1985) Expectancies versus background in the prediction of college drinking patterns. Journal of Consulting and Clinical Psychology 53:123–30.Google Scholar
Brown, S. A., Goldman, M. S., Inn, A. & Anderson, L. R. (1980) Expectations of reinforcement from alcohol: Their domain and relation to drinking patterns. Journal of Consulting and Clinical Psychology 48:419–26.Google Scholar
Bruehl, A. M., Lende, D. H., Schwartz, M., Sterk, C. E. & Elifson, K. (2006) Craving and control: Methamphetamine users' narratives. Journal of Psychoactive Drugs (Suppl. 3):385–92.CrossRefGoogle ScholarPubMed
Burnett, S., Sebastian, C., Cohen, K. K. & Blakemore, S. J. (2010) The social brain in adolescence: Evidence from functional magnetic resonance imaging and behavioural studies. Neuroscience & Biobehavioural Reviews. DOI: 10.1016/j.neubiorev.2010.10.011.Google Scholar
Campbell, J. C., Szumlinski, K. K. & Kippin, T. E. (2009) Contribution of early environmental stress to alcoholism vulnerability. Alcohol 43(7):547–54.CrossRefGoogle ScholarPubMed
Carey, R. J., DePalma, G., Damianopoulos, E., Hopkins, A., Shanahan, A., Müller, C. P. & Huston, J. P. (2004) Dopaminergic and serotonergic autoreceptor stimulation effects are equivalent and additive in the suppression of spontaneous and cocaine induced locomotor activity. Brain Research 1019:134–43.Google Scholar
Carey, R. J., Huston, J. P. & Müller, C. P. (2008) Pharmacological inhibition of dopamine and serotonin activity blocks spontaneous and cocaine-activated behaviour. Progress in Brain Research 172:347–60.CrossRefGoogle ScholarPubMed
Carr, G. V. & Lucki, I. (2010) The role of serotonin in depression. In: Handbook of the behavioral neurobiology of serotonin, ed. Müller, C. P. & Jacobs, B. L., pp. 493506. Academic Press.Google Scholar
Carrigan, M. H., Ham, L. S., Thomas, S. E. & Randall, C. L. (2008) Alcohol outcome expectancies and drinking to cope with social situations. Addictive Behaviors 33(9):1162–66.CrossRefGoogle ScholarPubMed
Castren, E. (2005) Is mood chemistry? Nature Reviews Neuroscience 6:241–46.Google Scholar
Cato, B. M. (1992) Youth's recreation and drug sensations: Is there a relationship? Journal of Drug Education 22:293301.Google Scholar
Cauli, O. & Morelli, M. (2005) Caffeine and the dopaminergic system. Behavioral Pharmacology 16:6377.Google Scholar
Charlson, F., Degenhardt, L., McLaren, J., Hall, W. & Lynskey, M. (2009) A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiology and Drug Safety 18(2):93103.CrossRefGoogle ScholarPubMed
Chen, C. Y. & Anthony, J. C. (2004) Epidemiological estimates of risk in the process of becoming dependent upon cocaine: Cocaine hydrochloride powder versus crack cocaine. Psychopharmacology (Berlin) 172:7886.Google Scholar
Chick, J. (1999) Can light or moderate drinking benefit mental health? European Addiction Research 5:7481.CrossRefGoogle ScholarPubMed
Childs, E. & de Wit, H. (2009) Amphetamine-induced place preference in humans. Biological Psychiatry 65(10):900904.CrossRefGoogle ScholarPubMed
Chisholm, J. S. (1993) Life-history theory and the development of reproductive strategies. Current Anthropology 34(1):124.Google Scholar
Chisholm, J. S. (1999) Death, hope, and sex: Steps to an evolutionary ecology of mind and mortality, Cambridge University Press.Google Scholar
Clarke, T. K. & Schumann, G. (2009) Gene-environment interactions resulting in risk alcohol drinking behaviour are mediated by CRF and CRF1. Pharmacology Biochemistry & Behavior 93(3):230–36.CrossRefGoogle ScholarPubMed
Clayton, D. H. & Wolfe, N. D. (1993) The adaptive significance of self-medication. Trends in Ecology & Evolution 8(2):6063.CrossRefGoogle ScholarPubMed
Conrod, P. J., Pihl, R. O., Stewart, S. H. & Dongier, M. (2000) Validation of a system of classifying female substance abusers on the basis of personality and motivational risk factors for substance abuse. Psychology of Addictive Behaviors 14:243–56.Google Scholar
Conrod, P. J., Stewart, S. H., Comeau, N. & Maclean, A. M. (2006) Efficacy of cognitive-behavioral interventions targeting personality risk factors for youth alcohol misuse. Journal of Clinical Child and Adolescent Psychology 35:550–63.Google Scholar
Cooper, M. L. (2006) Does drinking promote risky sexual behaviour? A complex answer to a simple question. Current Directions in Psychological Science 15(1):1923.CrossRefGoogle Scholar
Cooper, M. L., Frone, M. R., Russell, M. & Mudar, P. (1995) Drinking to regulate positive and negative emotions: A motivational model of alcohol use. Journal of Personal and Social Psychology 69:9901005.Google Scholar
Cooper, M. L., Russell, M. & George, W. H. (1988) Coping, expectancies, and alcohol abuse: A test of social learning formulations. Journal of Abnormal Psychology 97:218–30.Google Scholar
Cooper, M. L., Russell, M., Skinner, J. B., Frone, M. R. & Mudar, P. (1992) Stress and alcohol use: Moderating effects of gender, coping, and alcohol expectancies. Journal of Abnormal Psychology 101:139–52.Google Scholar
Cosmides, L. & Tooby, J. (1994) Origins of domain specificity: The evolution of functional organization. In Mapping the mind: Domain specificity in cognition and culture, ed. Hirschfeld, L. & Gelman, S., pp. 85116. Cambridge University Press.CrossRefGoogle Scholar
Cosmides, L. & Tooby, J. (1999) Toward an evolutionary taxonomy of treatable conditions. Journal of Abnormal Psychology 108(3):453–64.Google Scholar
Crawford, C. (2000) Evolutionary psychology: Counting babies or studying information-processing mechanisms. Annals of the New York Academy of Sciences 97:2138.Google Scholar
Crowe, L. C. & George, W. H. (1989) Alcohol and human sexuality: Review and integration. Psychological Bulletin 105(3):374–86.Google Scholar
Curran, H. V. (1991) Benzodiazepines, memory and mood: A review. Psychopharmacology (Berlin) 105:18.Google Scholar
Davey, J., Richards, N. & Freeman, J. (2007) Fatigue and beyond: Patterns of and motivations for illicit drug use among long-haul truck drivers. Traffic Injury Prevention 8:253–59.CrossRefGoogle ScholarPubMed
Davies, J. B. (1997) The myth of addiction, 2nd edition. Routledge.Google Scholar
De las Cuevas, C., Sanz, E. & De la Fuente, J. (2003) Benzodiazepines: More “behavioural” addiction than dependence. Psychopharmacology (Berlin) 167:297303.CrossRefGoogle ScholarPubMed
de Wit, H. & Stewart, J. (1981) Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology 75(2):134–43.CrossRefGoogle ScholarPubMed
Decker, M. W., Brioni, J. D., Bannon, A. W. & Arneric, S. P. (1995) Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implications for CNS therapeutics. Life Sciences 56:545–70.CrossRefGoogle ScholarPubMed
Del Boca, F. K., Darkes, J., Goldman, M. S. & Smith, G. T. (2002) Advancing the expectancy concept via the interplay between theory and research. Alcoholism, Clinical and Experimental Research 26(6):926–35.Google Scholar
Dere, E., Easton, A., Nadel, L. & Huston, J. P. (2008) Handbook of episodic memory. Elsevier.Google Scholar
Devineni, A. V. & Heberlein, U. (2009) Preferential ethanol consumption in Drosophila models features of addiction. Current Biology 19(24):2126–32.Google Scholar
Di Chiara, G. (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug and Alcohol Dependence 38:95137.CrossRefGoogle ScholarPubMed
Di Chiara, G. & Imperato, A. (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences USA 85:5274–78.Google Scholar
Di Chiara, G. & North, R. A. (1992) Neurobiology of opiate abuse. Trends in Pharmacological Sciences 13:185–93.Google Scholar
Donovan, J. E. & Richard, J. (1985) Structure of problem behavior in adolescence and young adulthood. Journal of Consulting and Clinical Psychology 53(6):890904.Google Scholar
Dudley, R. (2000) Evolutionary origins of human alcoholism in primate frugivory. The Quarterly Review of Biology 75(1):315.Google Scholar
Dudley, R. (2002) Fermenting fruit and the historical ecology of ethanol ingestion: Is alcoholism in modern humans an evolutionary hangover? Addiction 97:381–88.CrossRefGoogle ScholarPubMed
Eissenberg, T. & Balster, R. L. (2000) Initial tobacco use episodes in children and adolescents: Current knowledge, future directions. Drug and Alcohol Dependence 59(Suppl. 1):S4160.CrossRefGoogle ScholarPubMed
EMCDDA (European Monitoring Centre for Addictive Drugs) (2009) State of the drug problem 2009. http://www.emcdda.europa.eu/drug-situation.Google Scholar
Emley, G. S. & Hutchinson, R. R. (1983) Unique influences of 10 drugs upon post-shock biting attack and preshock manual responding. Pharmacology Biochemistry and Behavior 19:512.CrossRefGoogle Scholar
Everitt, B. J. & Wolf, M. E. (2002) Psychomotor stimulant addiction: A neural systems perspective. Journal of Neuroscience 22(9):3312–20.Google Scholar
Fantegrossi, W. E., Woolverton, W. L., Kilbourn, M., Sherman, P., Yuan, J., Hatzidimitriou, G., Ricaurte, G. A., Woods, J. H. & Winger, G. (2004) Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 29(7):1270–81.CrossRefGoogle ScholarPubMed
Feenstra, M. G. P., Botterblom, M. H. A. & Vanuum, J. F. M. (1995) Novelty-induced increase in dopamine release in the rat prefrontal cortex in-vivo – Inhibition by diazepam. Neuroscience Letters 189:8184.CrossRefGoogle ScholarPubMed
Felder, C. C. & Glass, M. (1998) Cannabinoid receptors and their endogenous agonists. Annual Reviews of Pharmacology and Toxicology 38:179200.Google Scholar
Feldman, R. S., Meyer, J. S. & Quenzer, L. F. (1997) Principles of Neuropsychopharmacology. Sinauer Associates.Google Scholar
Fischman, M. W. & Schuster, C. R. (1980) Cocaine effects in sleep-deprived humans. Psychopharmacology (Berlin) 72:18.CrossRefGoogle ScholarPubMed
Fischman, M. W. & Schuster, C. R. (1982) Cocaine self-administration in humans. Federal Proceedings 41:241–46.Google ScholarPubMed
Foltin, R. W. & Haney, M. (2000) Conditioned effects of environmental stimuli paired with smoked cocaine in humans. Psychopharmacology (Berlin) 149(1):2433.Google Scholar
Friedman, L. S., Lichtenstein, E. & Biglan, A. (1985) Smoking onset among teens: An empirical analysis of initial situations. Addictive Behaviors 10:113.CrossRefGoogle ScholarPubMed
Frolov, A. G. & Pavlova, O. G. (2003) Instrumentalization of movements evoked by stimulation of the motor cortex by food reinforcement in dogs. Neuroscience and Behavioral Physiology 33:203207.Google Scholar
Gable, R. S. (2004) Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99:686–96.Google Scholar
Garattini, S., Borroni, E., Mennini, T. & Samanin, R. (1978) Differences and similarities among anorectic agents. In: Central mechanisms of anorectic drugs, ed. Garattini, S. & Samanin, R.. Raven Press.Google Scholar
Gawin, F. H. (1991) Cocaine addiction: Psychology and neurophysiology. Science 251:1580–86.Google Scholar
Gawin, F. H. & Kleber, H. D. (1986) Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Archives of General Psychiatry 43:107–13.Google Scholar
Geyer, M. A. & Vollenweider, F. X. (2008) Serotonin research: Contributions to understanding psychoses. Trends in Pharmacological Sciences 29(9):445–53.Google Scholar
Glander, K. E. (1994) Nonhuman primate self-medication with wild plant foods. In: Eating on the wild side: The pharmacological, ecological, and social implications of using noncultigens, ed. Etkin, N. L., pp. 239–56. University of Arizona Press.Google Scholar
Glynn, R. J., LoCastro, J. S., Hermos, J. A. & Bosse, R. (1983) Social contexts and motives for drinking in men. Journal of Studies on Alcohol 44:1011–25.Google Scholar
Goldberg, S. R. (1975) Stimuli associated with drug injections as events that control behavior. Pharmacological Review 27(3):325–40.Google ScholarPubMed
Goldman, D., Oroszi, G. & Ducci, F. (2005) The genetics of addictions: Uncovering the genes. Nature Reviews Genetics 6:521–32.Google Scholar
Goldman, M. S., Brown, S. A., Christiansen, B. A. & Smith, G. T. (1991) Alcoholism and memory: Broadening the scope of alcohol-expectancy research. Psychological Bulletin 110(1):137–46.Google Scholar
Goldstein, P. J. (1990) Anabolic steroids: An ethnographic approach. NIDA Research Monographs 102:7496.Google ScholarPubMed
Gonzalez-Maeso, J. & Sealfon, S. C. (2009) Psychedelics and schizophrenia. Trends in Neurosciences 32:225–32.Google Scholar
Gouzoulis-Mayfrank, E. & Daumann, J. (2009) Neurotoxicity of drugs of abuse – The case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues in Clinical Neurosciences 11(3):305–17.Google Scholar
Green, A. R., Mechan, A. O., Elliott, J. M., O'Shea, E. & Colado, M. I. (2003) The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacological Reviews 55:463508.Google Scholar
Griffiths, R. R., Lamb, R. J., Sannerud, C. A., Ator, N. A. & Brady, J. V. (1991) Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology 103:154–61.Google Scholar
Grinspoon, L. & Hedblom, P. (2005) A historical overview of amphetamines. In: Amphetamines, ed. Harris, N., pp. 1930. Thomson Gale.Google Scholar
Gustafson, R. (1991) Is the strength and the desirability of alcohol-related expectancies positively related? A test with an adult Swedish sample. Drug and Alcohol Dependence 28:145–50.Google Scholar
Haber, S. N., Fudge, J. L. & McFarland, N. R. (2000) Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. The Journal of Neuroscience 20(6):2369–82.CrossRefGoogle ScholarPubMed
Hagen, E. H., Sullivan, R. J., Schmidt, R., Morris, G., Kempter, R. & Hammerstein, P. (2009) Ecology and neurobiology of toxin avoidance and the paradox of drug reward. Neuroscience 160(1):6984.Google Scholar
Hahn, B. & Stolerman, I. P. (2002) Nicotine-induced attentional enhancement in rats: Effects of chronic exposure to nicotine. Neuropsychopharmacology 27:712–22.Google Scholar
Hahn, B., Shoaib, M. & Stolerman, I. P. (2002) Nicotine-induced enhancement of attention in the five-choice serial reaction time task: The influence of task demands. Psychopharmacology (Berlin) 162:129–37.Google Scholar
Halberstadt, A. L. & Nichols, D. E. (2010) Serotonin and serotonin receptors in hallucinogen action. In: Handbook of the behavioral neurobiology of serotonin, ed. Müller, C. P. & Jacobs, B. L., pp. 621–36. Academic Press.CrossRefGoogle Scholar
Hamilton, W. D. (1964) The genetical evolution of social behaviour. I. Journal of Theoretical Biology 7:116.Google Scholar
Haney, M., Maccari, S., Le, M. M., Simon, H. & Piazza, P. V. (1995) Social stress increases the acquisition of cocaine self-administration in male and female rats. Brain Research 698:4652.CrossRefGoogle ScholarPubMed
Harding, W. & Zinberg, N. E. (1977) The effectiveness of the subculture in developing rituals and social sanctions for controlled drug use. In Drugs, rituals and altered states of consciousness, ed. Du Toit, B. M., pp. 111–33. A. A. Balkema.Google Scholar
Harper, C. (2007) The neurotoxicity of alcohol. Human & Experimental Toxicology 26(3):251–57.Google Scholar
Harris, R. A., Trudell, J. R. & Mihic, S. J. (2008) Ethanol's molecular targets. Science Signaling 1(28):re7.CrossRefGoogle ScholarPubMed
Harrison, A. A., Gasparini, F. & Markou, A. (2002) Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berlin) 160:5666.CrossRefGoogle ScholarPubMed
Heath, D. B. (2000) Drinking occasions: Comparative perspectives on alcohol and culture. Brunner/Mazel.Google Scholar
Heberlein, A., Bleich, S., Kornhuber, J. & Hillemacher, T. (2009) Benzodiazepine dependence: Causalities and treatment options. Fortschritte der Neurologie und Psychiatrie 77:715.CrossRefGoogle ScholarPubMed
Heilig, M. & Koob, G. F. (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends in Neurosciences 30:399406.Google Scholar
Heyman, G. M. (1996) Resolving the contradictions of addiction. Behavioral and Brain Sciences 19(4):561610.CrossRefGoogle Scholar
Heyne, A., May, T., Goll, P. & Wolffgramm, J. (2000) Persisting consequences of drug intake: Towards a memory of addiction. Journal of Neural Transmission 107(6):613–38.CrossRefGoogle ScholarPubMed
Higgins, S. T., Bickel, W. K., Hughes, J. R., Lynn, M., Capeless, M. A. & Fenwick, J. W. (1990) Effects of intranasal cocaine on human learning, performance and physiology. Psychopharmacology (Berlin) 102:451–58.Google Scholar
Hill, E. M. & Chow, K. (2002) Life-history theory and risky drinking. Addiction 97(4):401–13.CrossRefGoogle ScholarPubMed
Hill, E. M. & Newlin, D. B. (2002) Evolutionary approaches to addiction: Introduction. Addiction 97(4):375–79.Google Scholar
Ho, Y. J., Pawlak, C. R., Guo, L., Schwarting, R. K. (2004) Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. Behavioural Brain Research 149(2):135–44.Google Scholar
Hollerman, J. R. & Schultz, W. (1998) Dopamine neurons report an error in the temporal prediction of reward during learning. Nature Neuroscience 1:304309.Google Scholar
Hong, Z. Y., Huang, Z. L., Qu, W. M., Eguchi, N., Urade, Y. & Hayaishi, O. (2005) An adenosine A(2A) receptor agonist induces sleep by increasing GABA release in the tuberomammillary nucleus to inhibit histaminergic systems in rats. Journal of Neurochemistry 92:1542–49.Google Scholar
Howell, L. L. & Byrd, L. D. (1995) Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. The Journal of Pharmacology and Experimental Therapeutics 275(3):1551–59.Google Scholar
Huffman, M. A. (2003) Animal self-medication and ethno-medicine: Exploration and exploitation of the medicinal properties of plants. Proceedings of the Nutrition Society 62(2):371–81.Google Scholar
Hughes, J. R., Hatsukami, D. K., Mitchell, J. E. & Dahlgren, L. A. (1986) Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry 143:993–97.Google ScholarPubMed
Huston, J. P., Haas, H. L., Boix, F., Pfister, M., Decking, U., Schrader, J. & Schwarting, R. K. (1996) Extracellular adenosine levels in neostriatum and hippocampus during rest and activity periods of rats. Neuroscience 73:99107.CrossRefGoogle ScholarPubMed
Ikemoto, S. & Panksepp, J. (1999) The role of nucleus accumbens dopamine in motivated behavior: A unifying interpretation with special reference to reward-seeking. Brain Research Reviews 31:641.CrossRefGoogle ScholarPubMed
Ito, T., Suzuki, T., Wellman, S. E. & Ho, I. K. (1996) Pharmacology of barbiturate tolerance/dependence: GABAA receptors and molecular aspects. Life Sciences 59:169–95.Google Scholar
Iversen, L. L. (2000) The science of marijuana. Oxford University Press.Google Scholar
Jacobs, B. L. & Fornal, C. A. (2010) Activity of brain serotonergic neurons in relation to physiology and behavior. In: Handbook of the behavioral neurobiology of serotonin, ed. Müller, C. P. & Jacobs, B. L., pp. 153–62. Academic Press.Google Scholar
Jacobsen, L. K., Southwick, S. M. & Kosten, T. R. (2001) Substance use disorders in patients with posttraumatic stress disorder: A review of the literature. American Journal of Psychiatry 158:1184–90.Google Scholar
Javaid, J. I., Fischman, M. W., Schuster, C. R., Dekirmenjian, H. & Davis, J. M. (1978) Cocaine plasma concentration: Relation to physiological and subjective effects in humans. Science 202:227–28.Google Scholar
Jentsch, J. D. & Roth, R. H. (1999) The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–25.Google Scholar
Jessor, R. (1987) Problem-behavior theory, psychosocial development, and adolescent problem drinking. British Journal of Addiction 82(4):331–42.Google Scholar
Jo, Y. H., Talmage, D. A. & Role, L. W. (2002) Nicotinic receptor-mediated effects on appetite and food intake. Journal of Neurobiology 53:618–32.Google Scholar
Johanson, C. E., Balster, R. L. & Bonese, K. (1976) Self-administration of psychomotor stimulant drugs: The effects of unlimited access. Pharmacology Biochemistry and Behavior 4:4551.Google Scholar
Johanson, C. E. & Fischman, M. W. (1989) The pharmacology of cocaine related to its abuse. Pharmacological Reviews 41:352.Google ScholarPubMed
Johnson, C., Beaton, R. & Hall, K. (1975) Poison-based avoidance learning in nonhuman primates: Use of visual cues. Physiology & Behavior 14(4):403407.Google Scholar
Johnstone, B. M., Leino, E. V., Ager, C. R., Ferrer, H. & Fillmore, K. M. (1996) Determinants of life-course variation in the frequency of alcohol consumption: Meta-analysis of studies from the collaborative alcohol-related longitudinal project. Journal of Studies on Alcohol 57(5):494506.CrossRefGoogle ScholarPubMed
Jones, R. T. (1971) Marihuana-induced “high”: Influence of expectation, setting and previous drug experience. Pharmacological Reviews 23:359–69.Google Scholar
Kabbaj, M., Norton, C. S., Kollack-Walker, S., Watson, S. J., Robinson, T. E. & Akil, H. (2001) Social defeat alters the acquisition of cocaine self-administration in rats: Role of individual differences in cocaine-taking behavior. Psychopharmacology (Berlin) 158:382–87.Google ScholarPubMed
Kalivas, P. W., Sorg, B. A. & Hooks, M. S. (1993) The pharmacology and neural circuitry of sensitization to psychostimulants. Behavioural Pharmacology 4:315–34.Google Scholar
Kalivas, P. W. & Volkow, N. D. (2005) The neural basis of addiction: A pathology of motivation and choice. American Journal of Psychiatry 162:1403–13.Google Scholar
Kanayama, G., Brower, K. J., Wood, R. I., Hudson, J. I. & Pope, H. G. Jr. (2009) Anabolic–androgenic steroid dependence: An emerging disorder. Addiction 104:1966–78.Google Scholar
Kandel, E. R. (2001) The molecular biology of memory storage: A dialogue between genes and synapses. Science 294:1030–38.Google Scholar
Kelley, A. E., Cador, M. & Stinus, L. (1990) Exploration and its measurement. A psychopharmacological perspective. In: Neuromethods 13 – Psychopharmacology, ed. Boulton, A. A., Baker, G. B. & Greenshaw, A. J., pp. 95143. Humana Press.Google Scholar
Kendler, K. S., Jacobson, K. C., Prescott, C. A. & Neale, M. C. (2003b) Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. American Journal of Psychiatry 160:687–95.Google Scholar
Kendler, K. S., Prescott, C. A., Myers, J. & Neale, M. C. (2003a) The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Archives of General Psychiatry 60:929–37.Google Scholar
Kenny, P. J. & Markou, A. (2006) Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 31:1203–11.Google Scholar
Kester, K. M. & Barbosa, P. (1994) Behavioral responses to host food plants of two populations of the insect parasitoid Cotesia congregata (Say). Oecologia 99:151–57.Google Scholar
Khantzian, E. J. (1985) The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. American Journal of Psychiatry 142:1259–64.Google Scholar
Khantzian, E. J. (1997) The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry 4:231–44.Google Scholar
Kidorf, M., Sherman, M. F., Johnson, J. G. & Bigelow, G. E. (1995) Alcohol expectancies and changes in beer consumption of first-year college students. Addictive Behaviors 20(2):225–31.CrossRefGoogle ScholarPubMed
King, A. J., Johnson, D. D. & Van Vugt, M. (2009) The origins and evolution of leadership. Current Biology 19(19):R911–16.CrossRefGoogle ScholarPubMed
Kochakian, C. D. (1990) History of anabolic–androgenic steroids. NIDA Research Monographs 102:2959.Google ScholarPubMed
Koob, G. F. (1992) Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends in Pharmacological Sciences 13:177–84.Google Scholar
Koob, G. F. (1999) Stress, corticotropin-releasing factor, and drug addiction. Annals of the New York Academy of Sciences 897:2745.Google Scholar
Koob, G. F. & Le Moal, M. (1997) Drug abuse: Hedonic homeostatic dysregulation. Science 278:5258.CrossRefGoogle ScholarPubMed
Koob, G. F. & Le Moal, M. (2008) Addiction and the brain antireward system. Annual Review of Psychology 59:2953.Google Scholar
Koob, G. F., Sanna, P. P. & Bloom, F. E. (1998) Neuroscience of addiction. Neuron 21:467–76.CrossRefGoogle ScholarPubMed
Kramer, J. C., Fischman, V. S. & Littlefield, D. C. (1967) Amphetamine abuse – Pattern and effects of high doses taken intravenously. Journal of the American Medical Association 201:8993.Google Scholar
Kreek, M. J., Nielsen, D. A., Butelman, E. R. & Laforge, K. S. (2005) Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nature Neuroscience 8:1450–57.CrossRefGoogle ScholarPubMed
Kuntsche, E., Knibbe, R., Gmel, G. & Engels, R. (2005) Why do young people drink? A review of drinking motives. Clinical Psychology Review 25:841–61.CrossRefGoogle Scholar
Kuntsche, E., Knibbe, R., Gmel, G. & Engels, R. (2006) Who drinks and why? A review of socio-demographic, personality, and contextual issues behind the drinking motives in young people. Addictive Behavior 31:1844–57.Google Scholar
Lader, M. (1994) Anxiolytic drugs: Dependence, addiction and abuse. European Neuropsychopharmacology 4:8591.Google Scholar
Laland, K. N., Odling-Smee, J. & Feldman, M. W. (2000) Niche construction, biological evolution, and cultural change. Behavioral and Brain Sciences 23(1):131–46.CrossRefGoogle ScholarPubMed
Laland, K. N., Odling-Smee, J. & Myles, S. (2010) How culture shaped the human genome: Bringing genetics and the human sciences together. Nature Reviews Genetics 11(2):137–48.Google Scholar
Lavikainen, H. M., Lintonen, T. & Kosunen, E. (2009) Sexual behavior and drinking style among teenagers: A population-based study in Finland. Health Promotion International 24(2):108–19.Google Scholar
Le Foll, B. & Goldberg, S. R. (2006) Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berlin) 184:367–81.Google Scholar
Leigh, B. C. (1989) In search of the Seven Dwarves: Issues of measurement and meaning in alcohol expectancy research. Psychological Bulletin 105(3):361–73.Google Scholar
Leigh, B. C. & Stacy, A. W. (2004) Alcohol expectancies and drinking in different age groups. Addiction 99(2):215–27.CrossRefGoogle ScholarPubMed
Lende, D. H. (2005) Wanting and drug use: A biocultural approach to the analysis of addiction. ETHOS 33(1):100–24.Google Scholar
Lende, D. H. (2007) Evolution and modern behavioral problems. In: Evolutionary medicine and health: New perspectives, ed. Wenda Trevathan, E. O., Smith, E. O. & McKenna, J. J., pp. 277–90, Oxford University Press.Google Scholar
Lende, D. H., Leonard, T., Sterk, C. E. & Elifson, K. (2007) Functional methamphetamine use: The insider's perspective. Addiction Research and Therapy 15(5):465–77.CrossRefGoogle Scholar
Lende, D. H. & Smith, E. O. (2002) Evolution meets biopsychosociality: An analysis of addictive behavior. Addiction 97(4):447–58.Google Scholar
Leonard, K. E. & Das Eiden, R. (1999) Husband's and wife's drinking: Unilateral or bilateral influences among newlyweds in a general population sample. Journal of Studies on Alcohol Supplement 13:130–38.Google Scholar
Licata, A., Taylor, S., Berman, M. & Cranston, J. (1993) Effects of cocaine on human aggression. Pharmacology Biochemistry and Behavior 45:549–52.CrossRefGoogle ScholarPubMed
Liechti, M. E., Saur, M. R., Gamma, A., Hell, D. & Vollenweider, F. X. (2000) Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23:396404.Google Scholar
Lipton, R. I. (1994) The effect of moderate alcohol use on the relationship between stress and depression. American Journal of Public Health 84:1913–17.Google Scholar
Lisonbee, L. D., Villalba, J. J., Provenza, F. D. & Hall, J. O. (2009) Tannins and self-medication: Implications for sustainable parasite control in herbivores. Behavioural Processes 82(2):184–89.Google Scholar
Lozano, G. A. (1998) Parasitic stress and self-medication in wild animals. Advances in the Study of Behavior 27:291317.Google Scholar
Maier, H. W. (1926) Der Kokainismus. Georg Thieme.Google Scholar
Maisonneuve, I. M., Ho, A. & Kreek, M. J. (1995) Chronic administration of a cocaine “binge” alters basal extracellular levels in male rats: An in vivo microdialysis study. Journal of Pharmacology and Experimental Therapeutics 272:652–57.Google Scholar
Maloff, D., Becker, H. S., Fonaroff, A. & Rodin, J. (1981) Informal social controls and their influence on substance use. In: Control over intoxicant use: Pharmacological, psychological and social considerations, ed. Zinberg, N. E. & Harding, W., pp. 535. Human Science Press.Google Scholar
Mansvelder, H. D., van Aerde, K. I., Couey, J. J. & Brussaard, A. B. (2006) Nicotinic modulation of neuronal networks: From receptors to cognition. Psychopharmacology (Berlin) 184:292305.CrossRefGoogle ScholarPubMed
Marcuse, L. (1984) Philosophie des Glücks. Diogenes.Google Scholar
Markou, A. (2008) Neurobiology of nicotine dependence. Philosophical Transactions of the Royal Society London B Biological Sciences 363:3159–68.Google Scholar
Markou, A., Kosten, T. R. & Koob, G. F. (1998) Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology 18:135–74.Google Scholar
Marlatt, G. A. & George, W. H. (1984) Relapse prevention: Introduction and overview of the model. British Journal of Addiction 79(3):261–73.Google Scholar
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgansberger, W., Di Marzo, V. & Lutz, B. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–34.Google Scholar
Martel, P. & Fantino, M. (1996) Mesolimbic dopaminergic system activity as a function of food reward: A microdialysis study. Pharmacology Biochemistry and Behavior 53:221–26.Google Scholar
Matsumoto, M. & Hikosaka, O. (2009) Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature 459:837–41.CrossRefGoogle ScholarPubMed
Matthews, T. J., Abdelbaky, P. & Pfaff, D. W. (2005) Social and sexual motivation in the mouse. Behavioral Neuroscience 119(6):1628–39.Google Scholar
McBride, W. J., Le, A. D. & Noronha, A. (2002) Central nervous system mechanisms in alcohol relapse. Alcohol Clinical and Experimental Research 26:280–86.Google Scholar
McBride, W. J., Murphy, J. M. & Ikemoto, S. (1999) Localization of brain reinforcement mechanisms: Intracranial self-administration and intracranial place-conditioning studies. Behavioural Brain Research 101:129–52.Google Scholar
McCabe, S. E., Cranford, J. A., Boyd, C. J. & Teter, C. J. (2007b) Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addictive Behavior 32:562–75.Google Scholar
McCabe, S. E., Knight, J. R., Teter, C. J. & Wechsler, H. (2005) Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction 100:96106.CrossRefGoogle ScholarPubMed
McCabe, S. E., West, B. T. & Wechsler, H. (2007a) Alcohol-use disorders and nonmedical use of prescription drugs among U.S. college students. Journal of Studies on Alcohol and Drugs 68:543–7.Google Scholar
McGaugh, J. L. (2000) Memory – A century of consolidation. Science 287:248–51.Google Scholar
McLellan, A. T., Woody, G. E. & O'Brien, C. P. (1979) Development of psychiatric illness in drug abusers: Possible role of drug preference. New England Journal of Medicine 301(24):1310–14.Google Scholar
McMahon, L. R., Filip, M. & Cunningham, K. A. (2001) Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. Journal of Neuroscience 21:7781–87.Google Scholar
Mechoulam, R., Fride, E. & Di Marzo, V. (1998) Endocannabinoids. European Journal of Pharmacology 359:118.CrossRefGoogle ScholarPubMed
Mello, N. K. (1972) Behavioral studies of alcoholism. In: Biology of alcoholism, ed. Kissin, B. & Begleiter, H., pp. 210–19, Plenum Press.Google Scholar
Mengod, G., Cortes, R., Teresa Vilaro, M. & Hoyer, D. (2010) Distribution of 5-HT receptors in the central nervous system. In: Handbook of the behavioral neurobiology of serotonin, ed. Müller, C. P. & Jacobs, B. L., pp. 123–38. Academic Press.Google Scholar
Miller, C. S. (2001) Toxicant-induced loss of tolerance. Addiction 96(1):115–37.Google Scholar
Miller, G. (2000) Mental traits as fitness indicators. Expanding evolutionary psychology's adaptationism. Annals of the New York Academy of Sciences 907:6274.Google Scholar
Miller, P. M., Smith, G. T. & Goldman, M. S. (1990) Emergence of alcohol expectancies in childhood: A possible critical period. Journal of Studies on Alcohol 51:343–49.Google Scholar
Miller-Tutzauer, C., Leonard, K. E. & Windle, M. (1991) Marriage and alcohol use: A longitudinal study of “maturing out.” Journal of Studies on Alcohol 52(5):434–40.Google Scholar
Milner, B., Squire, L. R. & Kandel, E. R. (1998) Cognitive neuroscience and the study of memory. Neuron 20(3):445–68.Google Scholar
Mitchell, S. N. (1993) Role of the locus-coeruleus in the noradrenergic response to a systemic administration of nicotine. Neuropharmacology 32:937–49.CrossRefGoogle ScholarPubMed
Molnar, D. S., Busseri, M. A., Perrier, C. P. & Sadava, S. W. (2009) A longitudinal examination of alcohol use and subjective well-being in an undergraduate sample. Journal of Studies on Alcohol and Drugs 70:704–13.CrossRefGoogle Scholar
Mondaini, N., Cai, T., Gontero, P., Gavazzi, A., Lombardi, G., Boddi, V. & Bartoletti, R. (2009) Regular moderate intake of red wine is linked to a better women's sexual health. Journal of Sexual Medicine 6(10):2772–77.Google Scholar
Mooney, D. K. (1995) The relationship between sexual insecurity, the alcohol expectation for enhanced sexual experience, and consumption patterns. Addictive Behaviors 20(2):243–50.CrossRefGoogle ScholarPubMed
Müller, C. P. & Carey, R. J. (2006) Intracellular 5-HT 2C-receptor dephosphorylation: A new target for treating drug addiction. Trends in Pharmacological Sciences 27:455–58.Google Scholar
Müller, C. P., Carey, R. J., Huston, J. P. & De Souza Silva, M. A. (2007a) Serotonin and psychostimulant addiction: Focus on 5-HT1A-receptors. Progress in Neurobiology 81:133–78.Google Scholar
Müller, C. P., Carey, R. J., Wilkisz, M., Schwenzner, S., Jocham, G., Huston, J. P. & De Souza Silva, M. A. (2008) Acute anxiolytic effects of cocaine: The role of test latency and activity phase. Pharmacology Biochemistry & Behavior 89:218–26.Google Scholar
Müller, C. P., De Souza Silva, M. A. & Huston, J. P. (2007b) Double dissociating effects of sensory stimulation and cocaine on serotonin activity in the occipital and temporal cortices. Neuropharmacology 52:854–62.Google Scholar
Müller, C. P., Pum, M. E., Schumann, G. & Huston, J. P. (2010) The role of serotonin in drug addiction. In: The behavioral neurobiology of serotonin, ed. Müller, C. P. & Jacobs, B. L., pp. 507–46. Academic Press.Google Scholar
Müller, C. P., Thönnessen, H., Barros, M., Tomaz, C., Carey, R. J. & Huston, J. P. (2004) Hippocampus 5-HT(1A)-receptors attenuate cocaine-induced hyperlocomotion and the increase in hippocampal but not nucleus accumbens 5-HT. Hipppocampus 14:710–21.Google Scholar
NatCen/NFER and National Center for Social Research/National Foundation for Educational Research (2005) Smoking, drinking and drug use among young people in England 2005. London.Google Scholar
Nathanson, J. A., Hunnicutt, E. J., Kantham, L. & Scavone, C. (1993) Cocaine as a naturally occurring insecticide. Proceedings of the National Academy Sciences USA 90(20):9645–48.Google Scholar
Negrete, J. C. (1993) Effects of cannabis on schizophrenia. In: Cannabis: Pathophysiology, epidemiology, detection, ed. Nahas, G. G. & Latour, C., pp. 105–12. CRC Press.Google Scholar
Nesse, R. M. (2002) Evolution and addiction. Addiction 97:470–71.CrossRefGoogle ScholarPubMed
Nesse, R. M. & Berridge, K. C. (1997) Psychoactive drug use in evolutionary perspective. Science 278:6366.Google Scholar
Nestler, E. J. & Aghajanian, G. K. (1997) Molecular and cellular basis of addiction. Science 278:5863.Google Scholar
Newlin, D. B. (2002) The self-perceived survival ability and reproductive fitness (SPFit) theory of substance use disorders. Addiction 97:427–45.CrossRefGoogle ScholarPubMed
Niaura, R., Goldstein, M. & Abrams, D. (1991) A bioinformational systems perspective on tobacco dependence. British Journal of Addiction 86(5):593–97.Google Scholar
Nichols, D. E. (2004) Hallucinogens. Pharmacological Therapy 101(2):131–81.Google Scholar
Nilsen, P., Holmqvist, M., Hultgren, E., Bendtsen, P. & Cedergren, M. (2008) Alcohol use before and during pregnancy and factors influencing change among Swedish women. Acta Obstetrics and Gynecology of Scandinavia 87(7):768–74.CrossRefGoogle ScholarPubMed
NSDUH (2007) National Survey of Drug Use and Health. http://oas.samhsa.gov/researchers.cfm.Google Scholar
Nutt, D., King, L. A., Saulsbury, W. & Blakemore, C. (2007) Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369:1047–53.CrossRefGoogle ScholarPubMed
O'Brien, C. P., Childress, A. R., Ehrman, R. & Robbins, S. J. (1998) Conditioning factors in drug abuse: Can they explain compulsion? Journal of Psychopharmacology 12(1):1522.Google Scholar
O'Malley, P. M. & Johnston, L. D. (2002) Epidemiology of alcohol and other drug use among American college students. Journal of Studies on Alcohol Supplement l:2339.Google Scholar
O'Malley, P. M., Johnston, L. D. & Bachman, J. G. (1985) Cocaine use among American adolescents and young adults. NIDA Research Monographs 61:5075.Google Scholar
Olds, J. & Milner, P. (1954) Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. Journal of Comparative and Physiological Psychology 47:419–27.Google Scholar
Olmstead, M. C. (2006) Animal models of drug addiction: Where do we go from here? Quarterly Journal of Experimental Psychology (Colchester.) 59(4):625–53.Google Scholar
Orford, J. (2001a) Addiction as excessive appetite. Addiction 96(1):1531.CrossRefGoogle ScholarPubMed
Orford, J. (2008) Asking the right questions in the right way: The need for a shift in research on psychological treatments for addiction. Addiction 103(6):875–85.Google Scholar
Overton, D. A. (1968) Visual cues and shock sensitivity in the control of T-maze choice by drug conditions. Journal of Comparative and Physiological Psychology 66:216–19.Google Scholar
Page, J. E., Balza, F., Nishida, T. & Towers, G. H. (1992) Biologically active diterpenes from Aspilia mossambicensis, a chimpanzee medicinal plant. Phytochemistry 31(10):3437–39.CrossRefGoogle ScholarPubMed
Panksepp, J. B. & Lahvis, G. P. (2007) Social reward among juvenile mice. Genes Brain and Behavior 6(7):661–71.Google Scholar
Panksepp, J., Knutson, B. & Burgdorf, J. (2002) The role of brain emotional systems in addictions: A neuro-evolutionary perspective and new “self-report” animal model. Addiction 97(4):459–69.Google Scholar
Parsons, O. A. (1998) Neurocognitive deficits in alcoholics and social drinkers: A continuum? Alcohol Clinical and Experimental Research 22(4):954–61.Google Scholar
Pascual-Leone, A., Dhuna, A. & Anderson, D. C. (1991) Long-term neurological complications of chronic, habitual cocaine abuse. Neurotoxicology 12(3):393400.Google Scholar
Patrick, M. E. & Maggs, J. L. (2008) Short-term changes in plans to drink and importance of positive and negative alcohol consequences. Journal of Adolescence 31:307–21.Google Scholar
Patrick, M. E. & Maggs, J. L. (2009) Does drinking lead to sex? Daily alcohol-sex behaviors and expectancies among college students. Psychology of Addictive Behaviors 23(3):472–81.Google Scholar
Peele, S. & Brodsky, A. (2000) Exploring psychological benefits associated with moderate alcohol use: A necessary corrective to assessments of drinking outcomes? Drug and Alcohol Dependence 60:221–47.Google Scholar
Perkins, H. W. (1999) Stress-motivated drinking in collegiate and postcollegiate young adulthood: Life course and gender patterns. Journal of Studies on Alcohol 60:219–27.Google Scholar
Perkins, K. A. (1992) Effects of tobacco smoking on caloric intake. British Journal of Addiction 87:193205.Google Scholar
Perry, E. K. & Perry, R. H. (1995) Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain and Cognition 28:240–58.CrossRefGoogle ScholarPubMed
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjorkum, A. A., Greene, R. W. & McCarley, R. W. (1997) Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness. Science 276:1265–68.Google Scholar
Porrino, L. J., Lyons, D., Smith, H. R., Daunais, J. B. & Nader, M. A. (2004) Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. Journal of Neuroscience 24(14):3554–62.Google Scholar
Porter, A. C. & Felder, C. C. (2001) The endocannabinoid nervous system: Unique opportunities for therapeutic intervention. Pharmacology and Therapeutics 90:4560.Google Scholar
Post, R. M., Kotin, J. & Goodwin, F. K. (1974) The effects of cocaine on depressed patients. American Journal of Psychiatry 131:511–17.Google Scholar
Potvin, S., Stip, E. & Roy, J. Y. (2003) Schizophrenia and addiction: An evaluation of the self-medication hypothesis. Encephale 29:193203.Google Scholar
Pum, M., Carey, R. J., Huston, J. P. & Müller, C. P. (2007) Dissociating effects of cocaine and d-amphetamine on dopamine and serotonin in the perirhinal, entorhinal, and prefrontal cortex of freely moving rats. Psychopharmacology (Berlin) 193:375–90.Google Scholar
Pum, M. E., Huston, J. P., De Souza Silva, M. A. & Müller, C. P. (2008) Visual sensory-motor gating by serotonin activation in the medial prefrontal and occipital, but not in the rhinal, cortices in rats. Neuroscience 153:361–72.CrossRefGoogle Scholar
Quadros, I. M., Takahashi, A. & Miczek, K. A. (2010) Serotonin and aggression. In: Handbook of the behavioral neurobiology of serotonin, ed. Müller, C. P. & Jacobs, B. L., pp. 687714. Academic Press.Google Scholar
Quednow, B. B., Jessen, F., Kuhn, K. U., Maier, W., Daum, I. & Wagner, M. (2006) Memory deficits in abstinent MDMA (ecstasy) users: Neuropsychological evidence of frontal dysfunction. Journal of Psychopharmacology 20:373–84.Google Scholar
Quednow, B. B., Kuhn, K. U., Hoppe, C., Westheide, J., Maier, W., Daum, I. & Wagner, M. (2007) Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA (“Ecstasy”). Psychopharmacology (Berlin) 189:517530.Google Scholar
Quednow, B. B., Kuhn, K. U., Mossner, R., Schwab, S. G., Schuhmacher, A., Maier, W. & Wagner, M. (2008) Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms. Biological Psychiatry 64:434–37.Google Scholar
Quednow, B. B., Schmechtig, A., Ettinger, U., Petrovsky, N., Collier, D. A., Vollenweider, F. X., Wagner, M. & Kumari, V. (2009) Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: A replication study. Biological Psychiatry 66:614–20.Google Scholar
Ray, R., Schnoll, R. A. & Lerman, C. (2009) Nicotine dependence: Biology, behaviour, and treatment. Annual Review of Medicine 60:247–60.Google Scholar
Redish, A. D., Jensen, S. & Johnson, A. (2008) A unified framework for addiction: Vulnerabilities in the decision process. Behavioral and Brain Sciences 31(4):415–37.Google Scholar
Resnick, R. B., Kestenbaum, R. S. & Schwartz, L. K. (1977) Acute systemic effects of cocaine in man: A controlled study by intranasal and intravenous routes. Science 195:696–98.Google Scholar
Rezvani, A. H. & Levin, E. D. (2001) Cognitive effects of nicotine. Biological Psychiatry 49:258–67.Google Scholar
Rich, J. A. & Singer, D. E. (1991) Cocaine-related symptoms in patients presenting to an urban emergency department. Annals of Emergency Medicine 20:616–21.Google Scholar
Richardson, N. R. & Roberts, D. C. S. (1996) Progressive ratio schedules in drug self-administration studies in rats: A method to evaluate reinforcing efficacy. Journal of Neuroscience Methods 66(1):111.Google Scholar
Risner, M. E. & Jones, B. E. (1980) Intravenous self-administration of cocaine and norcocaine by dogs. Psychopharmacology 71(1):8389.Google Scholar
Ritz, M. C., Cone, E. J. & Kuhar, M. J. (1990) Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: A structure-activity study. Life Sciences 46:635–45.Google Scholar
Ritz, M. C. & Kuhar, M. J. (1989) Relationship between self-administration of amphetamine and monoamine receptors in brain – comparison with cocaine. Journal of Pharmacology and Experimental Therapeutics 248:1010–17.Google Scholar
Robbins, T. W. & Everitt, B. J. (1996) Neurobehavioural mechanisms of reward and motivation. Current Opinion in Neurobiology 6:228–36.Google Scholar
Robbins, T. W. & Everitt, B. J. (1999) Drug addiction: Bad habits add up. Nature 398(6728):567–70.Google Scholar
Robbins, T. W., Ersche, K. D. & Everitt, B. J. (2008) Drug addiction and the memory systems of the brain. Annals of the New York Academy of Sciences 1141:121.Google Scholar
Robinson, T. E. & Berridge, K. C. (1993) The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research Reviews 18:247–91.Google Scholar
Robinson, T. E. & Berridge, K. C. (2003) Addiction. Annual Reviews in Psychology 54:2553.Google Scholar
Robles, M., Aregullin, M., West, J. & Rodriguez, E. (1995) Recent studies on the zoopharmacognosy, pharmacology and neurotoxicology of sesquiterpene lactones. Planta Medica 61:199203.Google Scholar
Rodgers, B., Korten, A. E., Jorm, A. F., Christensen, H., Henderson, S. & Jacomb, P. A. (2000) Risk factors for depression and anxiety in abstainers, moderate drinkers and heavy drinkers. Addiction 95:1833–45.Google Scholar
Rodriguez, E., Aregullin, M., Nishida, T., Uehara, S., Wrangham, R., Abramowski, Z., Finlayson, A. & Towers, G. H. (1985) Thiarubrine A, a bioactive constituent of Aspilia (Asteraceae) consumed by wild chimpanzees. Experientia 41(3):419–20.CrossRefGoogle ScholarPubMed
Rodriguez, E. & Wrangham, R. (1993) Zoopharmacognosy: The use of medicinal plants by animals. Recent Advances in Phytochemistry 27:89105.Google Scholar
Room, R. (2000) The more drinking, the more fun; but is there a calculus of fun, and should it drive policy? Drug and Alcohol Dependence 60:249–50.Google Scholar
Ross, H. E. & Young, L. J. (2009) Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Frontiers in Neuroendocrinology 30(4):534–47.CrossRefGoogle ScholarPubMed
Rozin, P. & Kalat, J. W. (1971) Specific hungers and poison avoidance as adaptive specializations of learning. Clinical Psychology 78(6):459–86.Google Scholar
Salamone, J.D. (1996) The behavioral neurochemistry of motivation: Methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. Journal of Neuroscience Methods 64:137–49.Google Scholar
Samanin, R. & Garattini, S. (1993) Neurochemical mechanism of action of anorectic drugs. Pharmacology and Toxicology 73:6368.Google Scholar
SAMHSA (2005) National survey on drug use and health, Substance Abuse and Mental Health Services Administration, Rockville (http://oas.samhsa.gov/nhsda.htm#NHSDAinfo).Google Scholar
Sanchis-Segura, C. & Spanagel, R. (2006) Behavioural assessment of drug reinforcement and addictive features in rodents: An overview. Addiction Biology 11(1):238.Google Scholar
Sareen, J., McWilliams, L., Cox, B. & Stein, M. B. (2004) Does a U-shaped relationship exist between alcohol use and DSM-III-R mood and anxiety disorders? Journal of Affective Disorders 82:113–18.Google Scholar
Sarter, M. & Bruno, J. P. (1997) Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis. Brain Research Reviews 23:2846.CrossRefGoogle Scholar
Sarter, M., Hasselmo, M. E., Bruno, J. P. & Givens, B. (2005) Unraveling the attentional functions of cortical cholinergic inputs: Interactions between signal-driven and cognitive modulation of signal detection. Brain Research Reviews 48:98111.Google Scholar
Schultz, W. (2000) Multiple reward signals in the brain. Nature Reviews Neuroscience 1:199207.Google Scholar
Schumann, G. (2007) Okey Lecture 2006: Identifying the neurobiological mechanisms of addictive behaviour. Addiction 102:1689–95.Google Scholar
Schumann, G., Johann, M., Frank, J., Preuss, U., Dahmen, N., Laucht, M., Rietschel, M., Rujescu, D., Lourdusamy, A., Clarke, T. K., Krause, K., Dyer, A., Depner, M., Wellek, S., Treutlein, J., Szegedi, A., Giegling, I., Cichon, S., Blomeyer, D., Heinz, A., Heath, S., Lathrop, M., Wodarz, N., Soyka, M., Spanagel, R. & Mann, K. (2008) Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Archives of General Psychiatry 65:826–38.Google Scholar
Schumann, G., Rujescu, D., Kissling, C., Soyka, M., Dahmen, N., Preuss, U. W., Wieman, S., Depner, M., Wellek, S., Lascorz, J., Bondy, B., Giegling, I., Anghelescu, I., Cowen, M. S., Poustka, A., Spanagel, R., Mann, K., Henn, F. A. & Szegedi, A. (2003) Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts. Biological Psychiatry 54:1422–26.Google Scholar
Schwarting, R. K., Thiel, C. M., Müller, C. P. & Huston, J. P. (1998) Relationship between anxiety and serotonin in the ventral striatum. NeuroReport 9:1025–29.Google Scholar
Seefelder, M. (1996) Opium. Eine Kulturgeschichte, 3 ed. Nikol.Google Scholar
Segal, B. (1985) Confirmatory analyses of reasons for experiencing psychoactive drugs during adolescence. International Journal of Addiction 20:1649–62.Google Scholar
Seiden, L. S. & Sabol, K. E. (1996) Methamphetamine and methylenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destruction. NIDA Research Monographs 163:251–76.Google Scholar
Seiden, L. S., Sabol, K. E. & Ricaurte, G. A. (1993) Amphetamine: effects on catecholamine systems and behavior. Annual Review of Pharmacology and Toxicology 33:639–77.Google Scholar
Sen, B. (2002) Does alcohol-use increase the risk of sexual intercourse among adolescents? Evidence from the NLSY97. Journal of Health Economics 21(6):1085–93.Google Scholar
Shaham, Y., Shalev, U., Lu, L., de Wit, H. & Stewart, J. (2003) The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 168(1–2):320.CrossRefGoogle ScholarPubMed
Sheldon, P. W. & Aghajanian, G. K. (1990) Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriform cortex – Evidence for the involvement of a 5-HT2-activated interneuron. Brain Research 506:6269.Google Scholar
Sher, K. J., Grekin, E. R. & Williams, N. A. (2005) The development of alcohol use disorders. Annual Review of Clinical Psychology 1:493523.Google Scholar
Siegel, R. K. (1978) Cocaine hallucinations. American Journal of Psychiatry 135:309–14.Google Scholar
Siegel, S. (1988) Drug anticipation and the treatment of dependence. NIDA Research Monograph 84:124.Google Scholar
Simons, J., Correia, C. J. & Carey, K. B. (2000) A comparison of motives for marihuana and alcohol use among experienced users. Addictive Behavior 25:153–60.Google Scholar
Singer, M. S., Mace, K. C. & Bernays, E. A. (2009) Self-medication as adaptive plasticity: Increased ingestion of plant toxins by parasitized caterpillars. PLoS.One. 4(3):e4796.Google Scholar
Skinner, B. F. (1938) The behavior of organisms. Appleton.Google Scholar
Skog, O. J. (2000) Addicts' choice. Addiction 95(9):1309–14.Google Scholar
Skogen, J. C., Harvey, S. B., Henderson, M., Stordal, E. & Mykletun, A. (2009) Anxiety and depression among abstainers and low-level alcohol consumers. The Nord-Trondelag Health Study. Addiction 104:1519–29.Google Scholar
Solowij, N. (1998) Cannabis and cognitive functioning. Cambridge University Press.Google Scholar
Spanagel, R. (2009) Alcoholism: A systems approach from molecular physiology to addictive behavior. Physiological Reviews 89:649705.Google Scholar
Spanagel, R., Pendyala, G., Abarca, C., Zghoul, T., Sanchis-Segura, C., Magnone, M. C., Lascorz, J., Depner, M., Holzberg, D., Soyka, M., Schreiber, S., Matsuda, F., Lathrop, M., Schumann, G. & Albrecht, U. (2005) The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nature Medicine 11:3542.Google Scholar
Spealman, R. D. & Goldberg, S. R. (1978) Drug self-administration by laboratory animals: Control by schedules of reinforcement. Annual Review of Pharmacology and Toxicology 18:313–39.Google Scholar
Spear, L. P. (2000) The adolescent brain and age-related behavioral manifestations. Neuroscience and Biobehavioral Reviews 24:417–63.Google Scholar
Sprouse, J. S., Bradberry, C. W., Roth, R. H. & Aghajanian, G. K. (1990) 3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan. European Journal of Pharmacology 178:313–20.Google Scholar
Squire, L. R., Knowlton, B. & Musen, G. (1993) The structure and organization of memory. Annual Review of Psychology 44:453–95.Google Scholar
Stacey, D., Clarke, T. K. & Schumann, G. (2009) The genetics of alcoholism. Current Psychiatry Reports 11(5):364–69.Google Scholar
Steele, C. M. & Josephs, R. A. (1990) Alcohol myopia. Its prized and dangerous effects. The American Psychologist 45(8):921–33.Google Scholar
Steriade, M., Datta, S., Pare, D., Oakson, G. & Curro Dossi, R. C. (1990) Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. Journal of Neuroscience 10:2541–59.Google Scholar
Stillman, R., Jones, R. T., Moore, D., Walker, J. & Welm, S. (1993) Improved performance 4 hours after cocaine. Psychopharmacology (Berlin) 110:415–20.Google Scholar
Stolerman, I. (1992) Drugs of abuse: Behavioural principles, methods and terms. Trends in Pharmacological Sciences 13:170–76.Google Scholar
Streatfeild, D. (2001) Cocaine. An unauthorized biography. St Martin's Press.Google Scholar
Sullivan, R. J. & Hagen, E. H. (2002) Psychotropic substance-seeking: Evolutionary pathology or adaptation? Addiction 97(4):389400.Google Scholar
Sullivan, R. J., Hagen, E. H. & Hammerstein, P. (2008) Revealing the paradox of drug reward in human evolution. Proceedings of the Royal Society B: Biological Sciences 275:1231–41.Google Scholar
Sussman, S., Pentz, M. A., Spruijt-Metz, D. & Miller, T. (2006) Misuse of “study drugs”: prevalence, consequences, and implications for policy. Substance Abuse Treatment and Prevention Policy 1:15.Google Scholar
Tatarkiewicz, W. (1976) Analysis of happiness. Kluwer Academic Publishers.Google Scholar
Taylor, B., Rehm, J. & Gmel, G. (2005) Moderate alcohol consumption and the gastrointestinal tract. Digestive Disorders 23:170–76.CrossRefGoogle ScholarPubMed
Taylor, J., Fulop, N. & Green, J. (1999) Drink, illicit drugs and unsafe sex in women. Addiction 94(8):1209–18.Google Scholar
Teter, C. J., Falone, A. E., Cranford, J. A., Boyd, C. J. & McCabe, S. E. (2010) Nonmedical use of prescription stimulants and depressed mood among college students: Frequency and routes of administration. Journal of Substance Abuse Treatment 38(3):292–98.Google Scholar
Thiel, C. M., Müller, C. P., Huston, J. P. & Schwarting, R. K. (1999) High versus low reactivity to a novel environment: Behavioural, pharmacological and neurochemical assessments. Neuroscience 93(1):243–51.Google Scholar
Tinbergen, N. (1963) On aims and methods of ethology. Zeitschrift für Tierpsychologie 20:410–33.Google Scholar
Tooby, J. & Cosmides, L. (1992) The psychological foundation of culture. In: The adapted mind: Evolutionary psychology and the generation of culture, ed. Barkow, J., Cosmides, L. & Tooby, J., pp. 1939. Oxford University Press.Google Scholar
Tupala, E. & Tiihonen, J. (2004) Dopamine and alcoholism: Neurobiological basis of ethanol abuse. Progress in Neuropsychopharmacology and Biological Psychiatry 28:1221–47.Google Scholar
Tzschentke, T. M. (2007) Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade. Addiction Biology 12(3–4):227462.Google Scholar
Uekermann, J. & Daum, I. (2008) Social cognition in alcoholism: A link to prefrontal cortex dysfunction? Addiction 103(5):726–35.Google Scholar
Uher, R. (2009) The role of genetic variation in the causation of mental illness: An evolution-informed framework. Molecular Psychiatry 14(12):1072–82.Google Scholar
Usher, M., Cohen, J. D., Servan-Schreiber, D., Rajkowski, J. & Aston-Jones, G. (1999) The role of locus coeruleus in the regulation of cognitive performance. Science 283:549–54.Google Scholar
Vanderschuren, L. J. & Kalivas, P. W. (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacology (Berlin) 151(2–3):99120.Google Scholar
Villalba, J. J., Provenza, F. D., Hall, J. O. & Lisonbee, L. D. (2010) Selection of tannins by sheep in response to gastrointestinal nematode infection. Journal of Animal Science 88(6):2189–98.Google Scholar
Volkow, N. D., Hitzemann, R., Wang, G. J., Fowler, J. S., Wolf, A. P., Dewey, S. L. & Handlesman, L. (1992) Long-term frontal brain metabolic changes in cocaine abusers. Synapse 11(3):184–90.Google Scholar
Volkow, N. D., Wang, G. J., Fischman, M. W., Foltin, R. W., Fowler, J. S., Abumrad, N. N., Vitkun, S., Logan, J., Gatley, S. J., Pappas, N., Hitzemann, R. & Shea, C. E. (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827–30.Google Scholar
Volkow, N. D., Wang, G. J., Ma, Y. M., Fowler, J. S., Wong, C., Jayne, M., Telang, F. & Swanson, J. M. (2006) Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage 32(4):1782–92.Google Scholar
Volkow, N. D., Wang, G. J., Ma, Y. M., Fowler, J. S., Zhu, W., Maynard, L., Telang, F., Vaska, P., Ding, Y. S., Wong, C. & Swanson, J. M. (2003) Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. The Journal of Neuroscience 23(36):11461–68.Google Scholar
Wack, J. T. & Rodin, J. (1982) Smoking and its effects on body weight and the systems of caloric regulation. American Journal of Clinical Nutrition 35:366–80.Google Scholar
Wagner, F. A. & Anthony, J. C. (2002) From first drug use to drug dependence; developmental periods of risk for dependence upon marihuana, cocaine, and alcohol. Neuropsychopharmacology 26:479–88.Google Scholar
Wakefield, J. C. (1999) Evolutionary versus prototype analyses of the concept of disorder. Journal of Abnormal Psychology 108(3):374–99.Google Scholar
Waldorf, D., Reinarman, C. & Murphy, S. (1991) Cocaine changes: The experience of using and quitting, Temple University Press.Google Scholar
Ward, R. J., Lallemand, F. & de, W. P. (2009) Biochemical and neurotransmitter changes implicated in alcohol-induced brain damage in chronic or “binge drinking” alcohol abuse. Alcohol and Alcoholism 44(2):128–35.Google Scholar
Waskow, I. E., Olsson, J. E., Salzman, C. & Katz, M. M. (1970) Psychological effects of tetrahydrocannabinol. Archives of General Psychiatry 22:97107.Google Scholar
Weil, A. T. (1998) The natural mind. Houghton Mifflin Co.Google Scholar
Weir, E. (2000) Raves: A review of the culture, the drugs and the prevention of harm. Canadian Medical Association Journal 162:1843–48.Google Scholar
Weiss, R. D., Mirin, S. M., Michael, J. L. & Sollogub, A. C. (1986) Psychopathology in chronic cocaine abusers. American Journal of Drug and Alcohol Abuse 12:1729.Google Scholar
Wells, B. E., Kelly, B. C., Golub, S. A., Grov, C. & Parsons, J. T. (2010) Patterns of alcohol consumption and sexual behavior among young adults in nightclubs. American Journal of Drug and Alcohol Abuse 36(1):3945.Google Scholar
West, R. (2006) Theory of addiction. Blackwell.Google Scholar
White, B. P., Becker-Blease, K. A. & Grace-Bishop, K. (2006) Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of the American College of Health 54:261–68.Google Scholar
White, N. M. (1989) Reward or reinforcement: What's the difference? Neuroscience and Biobehavioral Reviews 13(2–3):181–86.Google Scholar
White, N. M. (1996) Addictive drugs as reinforcers: Multiple partial actions on memory systems. Addiction 91:921–49.Google Scholar
Wiens, F., Zitzmann, A., Lachance, M. A., Yegles, M., Pragst, F., Wurst, F. M., von Holst, D., Guan, S. L. & Spanagel, R. (2008) Chronic intake of fermented floral nectar by wild treeshrews. Proceedings of the National Academy of Sciences U.S.A 105(30):10426–31.Google Scholar
Wikler, A. (1973) Dynamics of drug dependence. Implications of a conditioning theory for research and treatment. Archives of General Psychiatry 28(5):611–16.Google Scholar
Williams, G. C. (1957) Pleiotropy, natural selection, and the evolution of senescence. Evolution 11:398411.Google Scholar
Williams, M. J. & Adinoff, B. (2007) The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 33:1779–97.Google Scholar
Williamson, E. M. & Evans, F. J. (2000) Cannabinoids in clinical practice. Drugs 60:1303–14.Google Scholar
Wilsnack, S. C. (1974) The effects of social drinking on women's fantasy. Journal of Personality 42:4361.Google Scholar
Wise, R. A. (1980) The dopamine synapse and the notion of “pleasure centers” in the brain. Trends in Neurosciences 9195.Google Scholar
Wise, R. A. (1994) A brief history of the anhedonia hypothesis. In: Appetite: Neural and behavioural base, ed. Legg, C. R. & Both, D. A., pp. 234–63, Oxford University Press.Google Scholar
Wise, R. A. (2002) Brain reward circuitry: Insights from unsensed incentives. Neuron 36(2):229–40.Google Scholar
Witkin, J. M., Savtchenko, N., Mashkovsky, M., Beekman, M., Munzar, P., Gasior, M., Goldberg, S. R., Ungard, J. T., Kim, J., Shippenberg, T. & Chefer, V. (1999) Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: Comparisons with methamphetamine. The Journal of Pharmacology and Experimental Therapeutics 288(3):1298–310.Google Scholar
Woicik, P. A., Stewart, S. H., Pihl, R. O. & Conrod, P. J. (2009) The Substance Use Risk Profile Scale: A scale measuring traits linked to reinforcement-specific substance use profiles. Addictive Behavior 34:1042–55.Google Scholar
Wolff, K. & Winstock, A. R. (2006) Ketamine: From medicine to misuse. CNS Drugs 20:199218.Google Scholar
Wonnacott, S. (1997) Presynaptic nicotinic ACh receptors. Trends in Neurosciences 20:9298.Google Scholar
Wood, R. I. (2004) Reinforcing aspects of androgens. Physiology Behavior 83(2):279–89.Google Scholar
Wood, R. I. (2008) Anabolic-androgenic steroid dependence? Insights from animals and humans. Frontiers in Neuroendocrinology 29:490506.Google Scholar
Wrangham, R. & Nishida, T. (1983) Aspilla spp. Leaves: A puzzle in the feeding behavior of wild chimpanzees. Primates 24(2):276–82.Google Scholar
Wyatt, R. J., Karoum, F., Suddath, R. & Fawcett, R. (1988) Persistently decreased brain dopamine levels and cocaine. Journal of the American Medical Association 259:2996.Google Scholar
Yokel, R. A. & Pickens, R. (1973) Self-administration of optical isomers of amphetamine and methylamphetamine by rats. The Journal of Pharmacology and Experimental Therapeutics 187(1):2733.Google Scholar
Young, A. M., Joseph, M. H. & Gray, J. A. (1993) Latent inhibition of conditioned dopamine release in rat nucleus accumbens. Neuroscience 54:59.Google Scholar
Zacny, J. P. & Lichtor, S. A. (2008) Nonmedical use of prescription opioids: Motive and ubiquity issues. Journal of Pain 9:473–86.Google Scholar
Zinberg, N. E. (1984) Drug, set, and setting: The basis for controlled intoxicant use. Yale University Press.Google Scholar
Zinberg, N. E., Harding, W. M., Stelmack, S. M. & Marblestone, R. A. (1978) Patterns of heroin use. Annals of the New York of Academy Sciences 311:1024.Google Scholar
Zinberg, N. E. & Jacobson, R. C. (1976) The natural history of “chipping.” The American Journal of Psychiatry 133(1):3740.Google Scholar
Zuckerman, M. (1990) The psychophysiology of sensation seeking. Journal of Personality 58:313–45.Google Scholar
Zvolensky, M. J., Vujanovic, A. A., Bernstein, A., Bonn-Miller, M. O., Marshall, E. C. & Leyro, T. M. (2007) Marijuana use motives: A confirmatory test and evaluation among young adult marijuana users. Addictive Behavior 32:3122–30.CrossRefGoogle ScholarPubMed
Figure 0

Figure 1. Drug memory systems based on normal memories that psychoactive drugs are likely to influence. A time line suggests the temporal order in which different types of drug memories are established. Drug instrumentalization relies mostly on episodic, semantic, and instrumentally conditioned drug memories. Escalating and compulsory drug use may further intensify these memories. Drug addiction is, in addition, characterized by a growing influence of drug habit and drug priming memories, as well as by classically conditioned drug memories.

Figure 1

Figure 2. A two-stage model of drug instrumentalization based on the interplay of different drug memories. Drug instrumentalization is based on previously learned instrumental behavior reflected at the level of the brain in stimulus-response and stimulus-action-outcome associations.